b e h r n g e r n g e l h e value innovationc n e n partn ers hip collaboration external partners plays important role boehringer ingelheims research development strategy enquired indep end ence innovation means us familyowned company boehringer ingelheim able support basic innovation research may lead new medicines breakthrough diabetes research long term inspiration boehringer ingelheim convinced broad horizon freedom think bring best ideas innovating together venture capital innovative ideas discovering new things together boehringer ingelheims commit ment research development zebrafish news sust aina bility concept proven worth space free creative thinking boehringer ingelheim takes responsibility environment without saying generates greater efficiency innovative imprint seeing different eyes products helping management need inspire teams improving sustainably reducing ecological footprintvalue innovation innovation time fundamental requirement driving force boehringer ingelheim researchdriven pharmaceutical company around world employees work day day develop novel efficacious medicines people animals field human pharmaceuticals boehringer ingelheims portfolio contains example compounds treatment respiratory diseases cardiovascular diseases diseases central ner vous system well metabolic infectious diseases cancers net sales billion euros boehringer ingelheim one worlds leading pharmaceutical companies founded company remains familyowned day social responsibility important element corporate culture boehringer ingelheim includes worldwide involvement social projects example initiative making health also caring employees respect equal opportunity reconc iling career family form foundation mutual cooperation company also focuses environmental protec tion sustainability everything enquired boehringer ingelheim w h n n v n e n u innovation important motivating force boehringer ingelheim researchdriven pharmaceutical company asked chairman shareholders committee board managing directors innovation mean personally innovation easiest grasp successful research new edicines christian boehringer chairman shareholders committee innovation boehringer ingelheim easiest grasp successful research new medicines began establishment scientific department given environment time shortly world war launch respiratory medication lobelin remarkable appreciating familyowned company best grow organically independently successful research development today firmly anchored shareholder cor porate understanding innovations swine vaccine ingelvac circoflex pradaxa stroke prevention atrial fibrillation latest data empareg outcome study highrisk patients type diabetes examples commitment enquired boehringer ingelheim things better simpler differently less resources value innovation applies every function organisation professor andreas barner chairman board managing directors dr wolfgang baiker innovation us boehringer ingelheim member board managing directors responsibility biopharmaceuticals operations things better simpler differently less resources better mean new therapeutic options better simpler also intelligent computer pro gramme shortens routine tasks innovation must benefit key stakeholders whether thing completely different may add value internal external boehringer ingelheim understanding complex science questions innovation simply things differently inventing early stage sometimes easily prevented thing new value behind obvious seeing somebody frown strict selection process innovation pharmaceutical company like ideas lead better ideas course new treatment paradigm treatment careful ones strive foster climate idiopathic pulmonary fibrosis ipf patients ofev innovation flourish also something intelligently efficiently benefit environment example emitting less carbondioxide concept value innovation applies every function organisation contribute share innovation enquired boehringer ingelheim making change friend enemy dr joachim hasenmaier member board managing directors responsibility animal health consumer health care chc remaining young company world around us con mind building stant change commitment value experience innovation means making change friend enemy value inno vation goes way beyond product innovation innovation everything culture hubertus von baumbach strategy products portfolios processes even member board managing directors behaviour attitude personal development responsibility finance innovation products means added value customers implies define innovation eyes time innovation way things means competitiveness rapidly changing environment constant improve ment innovation essentially remaining young mind building experience enquired boehringer ingelheim positively impact health world allan hillgrove member board managing directors responsibility pharma marketing sales innovation breakthrough adds significant value comes many forms could example product technology way operating many examples brilliant diverse innovation boehringer ingelheim recent one minds working together benefit diabetes compound empagli flozin proven trial cardiovascular towards goal death reduced per cent clearest external benefit shown innovation brings health benefits society eg dr andreas neumann product prevent death reduces time patients spend hospital gratifying member board managing directors company positively impact responsibility human resources health world innovation key driver company success today tomorrow directly linked brilliant diverse minds working together towards goal peoples perspective truly believe diversity inclusion unlock innovation drive market growth want lever age global power boehringer ingelheims diversity foster environment outsidethebox thinking encouraged employees proposing novel ideas leaders giving diverse voices airtime space unleash full innov ative potential researchdriven pharmaceutical company innovation boehringer ingelheim b r e k h r u g h n abe e r e e r c h boehringer ingelheim innovation primarily means able help people new effective medicines example empareg outcome trial patients type diabetes shown compound discovered developed boehringer ingelheim may prevent death c ardiovascular complications diagnosis type diabetes comes shock large amount advice control blood sugar patients many aware serious condi need quit smoking need start exercising tion really frequently doctor first tells much people helpful take patient diabetes lead death fact around one step time start changing diet give world someone dies diabetes every seven seconds smoking done begin exercise life expectancy people diabetes reduced however adjusting healthier lifestyle sufficient twelve years cardiovascular disease behind many people diabetes begin treatment half people diabetes medicines addition lowering blood sugar real healthy living habits best way prevent heart dis goals preventing longterm complications especially cardio ease stroke however many patients overwhelmed vascular increasing life expectancy innovation boehringer ingelheim recent ray hope people diabetes high risk cardiovascular disease empareg outcome trial major international study patients shown medication treat type diabetes pre vent death every third patient high risk cardiovascular events medication also resulted per cent reduced people risk allcause mortality per cent reduced risk hospitalisation heart failure results achieved work boehringer ingelheim research top standard care development innovative medicines midseptember boehringer ingelheim eli lilly company presented results empareg outcome study st european association study diabetes annual meeting stockholm experts reacted spontaneous applause recalls professor hansjrgen wrle global vice president medicine boehringer ingelheim never study medica billion euros tion treatment diabetes lowered death rate cardiovascular events see video patient type diabetes talking experience visit httpbitlyya research development zinman b et al empagliflozin cardiovascular outcomes expenditure mortality type diabetes n engl j med innovation many therapeutic areas boehringer ingelheim successful breakthroughs diabetes research pharmaceutical company also successfully developed innovative medications patients studies therapeutic areas respiratory diseases new therapeutic option patients suffer rare devastating disease idiopathic pulmo nary fibrosis ipf respiratory diseases ii maintenance treatment currently progress boehringer ingelheim chronic obstructive pulmonary disease copd introduced status december new maintenance product relieve symptoms adult patients cardiology specific reversal agent rapidly reverse effect oral anticoagulant dabigatran emergency situa tions important surgery required oncology treatment advanced nonsmall cell lung cancer boehringer ingelheim compound inhibit patients growth new blood vessels withholding nutrients tumour requires grow expand studies currently progress overall recruit status december n n v tio n n e e spir ion inspiration boehringer ingelheim se e n g h r u g h f f e r e nt e e getting know people cultures enriches work new perspectives boehringer ingelheim convinced broad horizon freedom think bring best ideas bright red chillies gleam afternoon sun market glance sign poverty hardship disease tamil nadu southern india heat oppressive instead abundance freshly picked fruit vege air dusty traders improvised wooden tables barrows tables prices equivalent euro cents real bargain sag weight heavily laden baskets full corn european employees boehringer ingelheim herbs spices brightness fruit vegetables wander south indian market april competes colourful saris customers carefully far cry supermarket prices used paying checking item see fresh enough quality back home right lively bartering price begins first inspiration boehringer ingelheim us leadership training instilling set values future culture within company want promote innovative thinking order improve access healthcare people today access difficulty manuela pastore manager boehringer ingelheim initiative making heal th november second group boehringer ingelheim managers taking part insights week india inspiration boehringer ingelheim frank kornely team leader cardiovascular marketing boehringer ingelheim germany initially hoped insights trip would help learn busi ness works region makes country people tick much happened journey truly viewing market today per exposure trip really exposed us new spective western tourists people earning average things new experiences unlike tradi indian wage indian rupees around euro tional seminars coachings didnt cents disposal amount people living learn loads facts market par region spend food every day anyone ticular methods solving problems market amount money quickly realises learned take closer look things next impossible buy enough good food says manuela question way think work pastore manager boehringer ingelheim initiative daytoday work take making health mmh set organised standards granted business leadership programme trip southern india colleagues world rules private lives taking part trip spend week familiarising might conduct completely daytoday life locals getting different standards today take picture local mmh initiative projects open flexible approach working boehringer ingelheim promotes innovative projects support standards actually take us healthcare ward whether budgeting managing team experience goes making health projects week india well daily life work everyone participants heads wants make personal contribution make difference using individ full images impressions ual skills abilities standardised solutions ideas apply across board simply put brakes motivation contribute inspiration boehringer ingelheim sabine nikolaus change head prescription medicine countries perspective regional centre vienna boehringer ingelheim inspiring austria making health projects india really impressed social entrepreneurs put projects together achieve much simple means fascinates approach talk people exam ine situation closely want understand really need develop solution solution bring improvement peoples perspec tive one consider improve ment western viewpoint convinced many important innovations trends field healthcare emerge social area travel lot daytoday work experience many different countries cultures work together diverse range company departments week india focused attention complexity diversity different countries markets environments many ways improve peoples health particular environment regard experience important per suaded three country managers team also take part insights week part insights week participants opportunity talk people hospitals primary healthcare clinics inspiration boehringer ingelheim krystian fikert mmh fellow founder ceo mymind centre mental wellbeing ireland mmh fellow took part insights trip find health care projects india exchange ideas fellows based high sui cide rate india psychological problems arising deeprooted caste system shocked much work done making health supports centres mental health india strengthens selfconfidence people local communities invaluable work create better mental health homeless community visit new nursery set rural region using social enterprise mymind pur mmh funds see become important point sues similar approach ireland put contact locals healthcare issues speak people mental health within everyones reach hospitals basic healthcare clinics find make care support accessible welltrained medical staff observe lack affordable need insights resources often gives rise creative pragmatic solutions week gave lots ideas dynamic ideas social entrepreneurs use model also help people develop also experience however bureaucratic developing countries india cultural obstacles well lack knowledge prevent develop ideas together people seeking medical care simple problems everyone benefits india saw firsthand european standards often much complex prac high levels poverty mental health tice seem first problems plague community week india participants heads full thought mymind could provide images impressions ideas says manuela pastore early intervention services deal high inspiration stay long time accompanying level suicide among students young people living realised much done developing countries inspiration boehringer ingelheim patrick buckley head sales executive manager ireland boehringer ingelheim uk expecting arrive poverty stricken country quickly ques tion view people met showed participants second happiness less dependent insights week say hello children childrens home material things mine definition poverty also learned question way solve problems ascertained example would relatively straightforward improve health lot children implementing simple hygiene rules first thought teach par ents rules simple solution first daytoday work also often leads question glance would really change peoples processes routines within team previously taken routines cultural attitudes long given daily professional lives participants term mmhsupported ashoka fellow insights india trip successful hardworking managers heading came idea much regional teams experts medical field developing marketing effective children make soap campaigns managing sales key european markets first glance part school project give daytoday work much common daily lives parents present anyone people india mmh projects precisely change children knows parents proud perspective break entrenched daily routines values gifts want give children thought patterns inspiring even weeks months pleasure seeing make use trip participants still getting touch us theyve experiences broadened come idea making health programme horizons reminded important want recommend young leaders take part next insights keep open mind approaches week india successfully tried innovative go beyond usual solutions attitudes approaches teams daily work inspiration boehringer ingelheim l p n g e c h oth e r deeplyembedded boehringer ingelheims corporate culture helping people learning appreciating differences culture language particularly important boehringer ingelheim international company people nations working corporate headquarters ingelheim germany great sympathy within company everyday lives large number refugees germany comes surprise empathy respect fundamental pillars cor porate culture boehringer ingelheim says stefan rinn country man ager germany thats also attitude take towards people come us refugees treat empathy respect learn boehringer ingelheim event cooking friends instance refugee families migrants sponsors company prepare food together get know contacts even evolving friendships company workshops state institution asylum seekers deportees ingelheim example refugees learn something germany also given opportunity say find really strange country learning inspiration boehringer ingelheim volunteering patients seeking doctors nurses nurse practitioners employees boehringer ingelheims ridgefield site usa responded appeal donate time skills serve patients without health insurance registered nurse tricia keller volunteers boehringer ingelheim americares free clinic neighbouring danbury uninsured patients per year receive medical help past years boehringer ingelheim cares foundation donated million us dollars improve clinic enable help patients support boehringer ingelheim goes far beyond financial commitment employees also volunteer spanish portuguese interpret ers help patients speak providers volunteer ing gives opportunity help patients see life different perspective says tricia truly enriches life happy feet getting fresh air one best sources inspiration many people bring movement employees lives boehringer ingelheim set happy feet campaign china three months employees encouraged make part journey work foot start campaign company organised walking challenge may day boehringer ingelheim employees clocked kilometers corresponding width china west east boehringer ingelheim converted distance money thus able donate around yuan euros childrens hospital shanghai inspiration boehringer ingelheim n g eme nt n e e boehringer ingelheim making health n p r e th e r te ams making health mmh shawn liu initiative employees boehringer ingelheim global hr strategy trans five years supporting inspiring innovations formation lead former global improving healthcare throughout world head leadership develop ment commitment one first participants new experiences order help making health insights keep open mind require india week trip inspire ments increasingly complex personally fast moving global economy inspired first foremost sights programme makes important many impressive people contribution management boehringer ingelheim employees fortunate meet people run operates environment com involved mmh initiatives ngos hospital managers selfhelp pletely new learn group managers manage ngos social entrepreneurs lead inspiration difficult demanding projects teams passion motivation modesty passion order im often conditions great prove peoples quality life see uncertainty partly enormous projects succeed quite natu pressure limited resources rally employ means available people show leader experience important ship accomplish guided management shared values pursue clear success future de healthcare innovations goal learn lot players pend management staff social sector ideas position deal innovatively per support partnerships leadership style manent change well completely new environments diverse range making health players recognise sights programme becoming fixed promote good ideas matter part global leadership develop come innovation occurs ment programme boehringer ingel motivated people give heim management must inspire teams exposure important compo allow inspired nent management development new experiences impressions time global ideas competitions management always face n n v tio n n e e part ner ship partn ers hip boehringer ingelheim n v n g g e h e r paola casarosa started working boehringer ingelheims laboratories today looking external partners field prescription medicines involves casting wide net world knowing important partnerships biotech startups developing innovations partn ers hip boehringer ingelheim paving way external partnerships helping ensure pipeline always wellstocked new medicines boston one worlds biotech hotspots dr paola casarosa talks meetings tant present person meet right startups academic institutions boston people says strategy prescription quickly becomes passionate biotech medicines substantial external component scene oneofakind whenever im dr casarosa comes turin italy im fascinated rapidly biomedical sci graduated medical chemistry com ence evolving new biotechs ventures pleted doctorate molecular pharmacology investors every time even people netherlands holding several posts excited entrepreneurial atmosphere pharmaceutical companies moved one breathes says boehringer ingelheim initially working corporate vice president busi research joining business develop ness development licensingprescription ment team last three years medicines boehringer ingelheim visits working developing therapeutic alliances city us east coast several times year strategic partnerships paving way strengthen boehringer ingelheims visibility part external partnerships helping ensure ner choice get know potential new part pipeline always wellstocked new ners one colleagues also permanent medicines fixture office boston impor partn ers hip boehringer ingelheim thus working key interface within com thomson reuters first time named boehringer ingelheim pany boehringer ingelheim consistently built partner one innovative companies industries ships biotechs recent years today around per cent search partnerships driven ambition fill programmes early middle stages boehringer therapeutic gaps says dr casarosa work characterised ingelheims pipeline external innovation component scientific medical rationale paying biotech academia boehringer ingelheim wants invest even partnerships next five years company set spend billion euros cooperations external partners successful partnerships partnerships early stages boehringer ingelheim works successfully external partners research effective integrate many innovative ideas possible research development projects examples way creating greatest benefit sides oncology boehringer ingelheim concluded exclusive licensing agreement korean company hanmi pharma ceutical partners want work together develop targeted dr casarosa regularly visits biotechnology hotspots therapy patients lung cancer display particular besides boston also san francisco tokyo type mutation field cancer immunotherapy team held partnering days cities past boehringer ingelheim working tbingenbased com three years order facilitate dialogue promising pany curevac develop therapeutic tumour vaccine institutions startups invitationonly events offer personal way engage innovators focus early clinical arena boehringer ingelheim recently oneonone interactions roundtable discussions seeking exercised option acquired investigational drug open feedback established future partners pharmaxis ltd treat progressive liver condition boehringer ingelheims partnering approach specific needs nonalcoholic steatohepatitis nash partnerships early stages research effec tive way creating greatest benefit sides together californian company circuit therapeutics underlines dr casarosa helps us create right working boehringer ingelheim works optogenetic methods identify relationship best position compound platform new therapy approaches psychiatric cardiometabolic jointly shaping development diseases researchdriven pharmaceutical company boehringer ingelheim draws global network thats important partners capabilities transform research findings successful new medicines help patients need says dr casarosa boehringer ingelheims track record product approvals regulatory agencies speaks company gained new approvals total eleven new drug treat ments either us food drug administration fda european medicines agency ema good reason boehringer ingelheim ranked among top ten innovative companies idea pharma nominates year addition news agency partn ers hip boehringer ingelheim n u r e c p l f r n n v v e e boehringer ingelheims venture fund equipped million euros invested portfolio different biotech startups promising therapeutic ideas according dr frank kalkbrenner head venture fund boehringer ingelheim expressly looking additional partnerships partn ers hip boehringer ingelheim boehringer ingelheim venture fund facts figures initial capital dr kalkbrenner kind companies investing always looking young companies research socalled scientific platforms say novel therapeutic concepts new disease mechanisms therapeutic modalities potential application different indication areas good example vaccines naturally primarily prevent infections act prophylactically million euros vaccines also employed therapeutically tumours particular stimulate immune system attack tumour cells new scientific platforms looking also outside holdings startups therapeutic areas boehringer ingelheim typically focus early stage eg financing ing example companies shareholders currently research development working topics like tissue regeneration treatment hearing loss clinical proof concept new therapeutic principle new therapeutic modalities gene therapy treatment ophthalmologic diseases boehringer ingelheim get investment possible depending startups holdings ear ground latest development developments biotech industry would otherwise access knowledge knowhow within framework therapeutic areas beyond founders biotech compa total investment nies also benefit participation beyond financing aspects true winwin partnership member supervisory board actively contribute development companies building experience drug discovery development help shape strategies assist decision making addition using network support searching new partners additional investors needed longterm partnerships possible boehringer ingelheim investment highly innovative also risky area like little smart bet every project leads success near million euros per company future assume one boehringer ingelheim partner ships come venture fund portfolio optimal outcome venture capital equity investment go colleague business development licensing paola casarosa tell look portfolio investments young mainly company made exciting invention need speak technologyoriented companies explore potential collaboration boehringer ingelheims promising simultaneously research development uncertain future partn ers hip boehringer ingelheim c v e r n g n e w h n g g e h e r crowdsourcing cooperations public institutions universities boehringer ingelheims research development focuses variety external partnerships new approaches exploring external innovation crowdsourcing initiatives academics bring together best scientists groundbreaking new approaches attempt solve complex medical questions example boehringer ingelheim initi ated crowdsourcing project uniting interdisciplinary team boehringer ingelheim expands bilat experts around world research new diseasemodifying eral partnerships universities approaches treatment chronicobstructive pulmonary disease copd globally million people currently affected copd figure rising forecasts predict disease bilateral partnerships universities major pillar worlds thirdbiggest cause death boehringer ingelheim boehringer ingelheims approach researching new therapy options financing research project four years researchers ie new disease mechanisms new therapeutic modalities tech working biomed x innovation center campus nologies one new cooperation example university university heidelberg germany biomed x takes scientific requests texas md anderson cancer center develop new medicines pharma companies collects research proposals via internet treatment pancreatic cancer accounts four per cent cancer applicants selects best proposals builds team researchers deaths worldwide effective medicines therefore urgently needed heidelberg facility working closely pharma scientists addition company concluded four new partnerships university groups renowned institutes together icahn school medicine mount sinai massachusetts general hospital scripps research institute weill cornell medicine boehringer ingelheim explore companies public institutions microbiome eg gut microflora discover new approaches research together success treatment inflammatory bowel disease ibd crohns disease ulcerative colitis collaborations aim identify new within medical research publicprivate partnerships bring biomarkers guide clinical studies well new therapeutic targets best academic private researchers together around table jointly validated offer potential innovative medicines basic research precompetitive space partnerships address significant unmet medical need ibd patients increasingly result major progress advantageous involved examples open partnerships companies scientific institutions include structural genomics consortium sgc innovative medicines initiative imi gprotein coupled receptor gpcr consortium boehringer ingelheim plays active role together researchdriven pharmaceutical companies universities scientific institutions partn ers hip boehringer ingelheim boehringer ingelheims commitment research development billion euros billion euros billion euros assigned amount preclinical research boehringer ingelheim investing invested partnerships development rd including medicine year external partners innovations early middle research phases come external partnerships n n v tio n ne e sus ta abi l im p r v n g u n b l brazil solana farm boehringer ingelheim taking responsibility nature climate goes without saying time generates greater efficiency innovative products sus tain ability boehringer ingelheim adrian von treuenfels head solana farm brazil boehringer ingelheim cultivates medicinal plants little paradise starts right next fields plants date years reforesta dozens birds fly dense treetops blue tion initial areas hectares butterflies flutter coati trots covered young forest every year refor trees bushes shrubs grow together rampantly ested area binds ten tonnes co explains native forest surrounds cropland solana von treuenfels farm southern brazil although much planting trees may one phar planted human hand maceutical companys main areas business kilometres west paolo boehringer sustainability always important topic ingelheim cultivating medicinal plant staff boehringer ingelheim everyone used make antispasmodic precursor society company alike benefits medicines buscopan spiriva erosion extent solana farm instance medicinal makes farming difficult result plants planted along contour lines provides decided mids reforest steep additional protection erosion pesticides slopes going water says head used subject strictest criteria farm adrian von treuenfels employees col protects environment makes land lected seeds seedlings native forests nur fertile long term ecosystem remains tured saplings planted largely intact sus tain ability boehringer ingelheim native forest surrounds farmland solana farm provides habitat numerous animals coatis butterflies mids boehringer ingelheim decided partly reforest area solana farm today matter course always ask impact actions sustainable says dr andreas gbler responsible boehringer ingelheim green initiative aim enable company reduce emissions co equivalents per cent euro revenues earned compared boehringer ingelheim making whatever savings terms energy resources least innovations well efficient environ mentally friendly products processes sus tain ability boehringer ingelheim boehringer ingelheim takes totally new paths respimat pictures assembly dortmund germany manufacturing respimat inhaler dortmund medicine powder form instead liquid boehringer facility germany case point many ways much ingelheim pursues course handihaler common distant solana farm brazil one pharmaceutical companies also switched powder thing respimat device enables people chronic inhalers devices ideal everyone however lung disease inhale medicine spiriva fine patient able inhale deeply mist medicine enters even small airways fine powder enter lungs spiriva whose active substance comes medicinal time therefore decided take completely plants solana farm new path explains dr joachim eicher senior expert respimat brazilian farm share respimat manufacturing department codeveloped similarities terms innovations protecting climate inhalers nozzle boehringer ingelheim years ago montreal protocol came force respimat came onto market features boehringer ingelheim management decided drastically spring forces liquid medicine tiny little reduce chlorofluorocarbon cfc emissions result nozzles mechanical pressure technique creates damage ozone layer meant mist around million micrometresize droplets better solution found standard pocket inhal technical milestone also benefits global climate ers day since contained environ propellant standard devices constitutes g co mentally harmful propellants converted liquid medi equivalent per inhaler often used cine stored cartridge fine droplets one best month save per cent emissions says alternatives available time inhaler deliver dr eicher pride sus tain ability boehringer ingelheim mouthpiece uniblock dosing chamber dose release button upper housing spring capillary tube clear base injection moulding cartridge respimat plastic components boehringer ingelheim continually working office heated using hotwater pipes towards becoming sustainable many small concrete ceilings projects contribute reducing greenhouse progress also made existing gases also importance buildings another example ingelheim construction bi ingelheim boehringer site shows pharmaceutical active substance ingelheims largest administration building world building boehringer ingelheim switched wide designed use little energy pos lighting system energysaving technology sible heat exchangers recover heat extracted cooling systems control rooms air summer ventilation system cools turned degrees heat recovery space using cool air results water optimised result buildings energy con evaporates effect airconditioning system sumption decreased around per cent use additional electricity alone october respimat production facility received environmental certification iso standards sus tain ability boehringer ingelheim dr gbler report boehringer ingelheim able decrease co emissions biggest sites per cent relation energy consumption floor space ratio ie total floor space storeys building weve come long way yet keep getting better every level says dr gbler company also rewarded farsightedness new law came force brazil years ago within short period time per cent area owned farms forested von treuenfels head solana farm new regulation problem thanks reforestation project immediately fulfilled quota boehringer ingelheim paid particular attention environmental aspects building bi largest administrative building worldwide reducing eco boehringer ingelheim sustainability logical footprint sound basis boehringer ingelheim wants even sustainable reason professor andreas barner chairman board managing directors signed responsible care global charter july concerns com mitment chemical industry sustainability everyday corporate life examples current initiatives waste ridgefield facility usa boehringer ingelheim tries avoid waste wherever possible remaining waste used generate energy rest recycled wherever possible proportion recycled waste increased per cent per cent result dangerous pharmaceuti cal waste ends landfill also reduces risk polluting soil groundwater clean fleet energy consumption airconditioning heating systems boehringer ingelheim facilities china japan set fixed temperatures airconditioning system boehringer ingelheim headquar ters japan operates office hours thanks changes energy consumption significantly lowered wastewater many facilities boehringer ingelheim operates modern water treatment plants ensure complete compliance legal limits one example spanish malgrat de mar facility wastewater processed three biological steps filtered sand resources germany boehringer ingelheim introduced paper made per cent recycled fibres also carries blue angel sustainability certification mkg reduction co emissions relating energy consumption floor space ratio key facilities since boehringer ingelheim vehicle fleet germany trend co emissions boehringer ingelheim company cars mkg mkg sus tain ability boehringer ingelheim target electric vehicles n n v tio n ne e ep en dence z e b r f h n e w privately owned pharmaceutical company boehringer ingelheim focused research development years companys curiosity enables support basic research may lead new medicines long term inde pen dence boehringer ingelheim toddler discovered chance minute biggest sponsor sole shareholder signal peptide named toddler small size intervene projects research fields seemingly unsteady movement plays major role currently scientists work studying development zebrafish danio rerio basics molecular biology independent embryo missing heart develop institute one remit conduct basic properly significance protein research highest possible level zebrafish remained undiscovered decades pays period years imp mids studies fish embryo seemed authors published scientific quite complete scientists thought articles registered patents five imp discovered everything know says researchers also received austrias highest dr andrea pauli scientist discovered toddler endowed research prize wittgenstein award dr pauli group leader boehringer ingelheim currently expanding research institute molecular pathology imp commitment imp investing around million vienna austria since september boehringer euros construction new building fea ingelheim supports basic research institute turing new spacious laboratory areas important toddler zebrafish remained undiscovered decades inde pen dence boehringer ingelheim dr paulis innovative discovery would possible without independence basic researcher without independence basic researcher dr paulis innova tive discovery would possible freedom pursue sidetrack studies eventually led toddler researcher fact trying track completely different mechanism perhaps toddler one day find way basic research boehringer ingelheim biomedical laboratories toddler peptide cellular component many forms life including humans however actual function still unknown similar peptide called apelin currently enjoying significant attention pharmaceutical research community would great able discover something basic research could ultimately used medicine thereby help people imp researcher dr pauli saysinde pen dence boehringer ingelheim h e c n c e pt h p r v e n w rth inde pen dence boehringer ingelheim dr janmichael peters headed research institute molecular pathology imp vienna austria since interview explains pharmaceutical industry benefits independent basic research dr peters institute conducts basic research inno ogy pharmaceutical research concept proven vation need independence way scien worth think admirably farsighted strategy tists come new ideas boehringer ingelheim also works well company dr janmichael peters yes convinced privately owned enables plan act longer case possible break new ground want term pharmaceutical companies also exploring new understand things primary interest cure diseases directions dont imp inspiring try want understand biological processes actually func certain new ideas tion cell division choose path cant know advance journey take ideal case pharmaceutical research leads new medicine innovative therapy last time sounds like unlimited intellectual freedom institutes research contributed discovery exactly freedom extremely important johannes zuber physician molecular biologist without would able first one group leaders searches new possibilities tar make biological discoveries also way geted cancer therapy approach find cancer cells attract best curiousitydriven scientists would weak points serve possible targets novel drugs access kind people suspected able identify gene brd could conducting contract research considered achilles heel acute myeloid leukaemia particularly aggressive form blood cancer today four allowed research completely independently years discovery several brd inhibitors already expectation boehringer ingelheim basic clinical testing research highest international level discover link could practical applications delighted see responsibility scientists give something back human kind approach research team boehringer ingelheim tell discovered something might interest founding imp intended establish stronger link molecular biol inde pen dence boehringer ingelheim space free creative thinking readiness keeping family tradition give preference leaving acquired means company fundamental significance future statement ernst boehringer younger son company founder albert boehringer confirmed belief tire less safeguarding economic independence would continue decisive importance success familyowned company entrepreneur humanisti cally inclined world citizen saw essential basis innovative ambition pharmaceutical research well humanities throughout life ernst boehringer demanded promoted safeguarding valuable asset establishing space employees pursue free creative thinking indispensable innovation also constantly enabled technical basis research development medicines highest possible level good reason well aware one depended actually made possible conviction important innovation thanks independence independence thanks anticipate things innovation ernst boehringer worked fought life otherwise late dr michael siebler ernst boehringer head boehringer ingelheim company archive courage keep things independent researchdriven pharmaceutical company needs lot capi founder boehringer ingelheim albert boehringer tal every active substance becomes pharmaceu attempting discover citric acid stumbled across tical medicine lots approaches turn dead ends thing else entirely lactic acid boehringer made courageous boehringer ingelheim shareholder family see decision continued research supposed mistake reason make shortterm investments built lactic acid industry constantly reinvested contrary independent ups downs profits research thus paved way company capital market shareholders greater staying boehringer ingelheim know today power good example company history imprint boehringer ingelheim f u h ave n q u er es r c mm e nt p le e n h es tate c nta ct u boehringer ingelheim gmbh binger strae ingelheim germany telephone fax contact corporate division communications email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom issued boehringer ingelheim gmbh concept design layout mpm corporate communication solutions mainz wwwmpmde photos illustrations rainer mirau p marion carniel p research institute molecular pathology p lennart nilsson p getty images p simone silbernagel mpm p fotolia p dieth schrder fotografie p julio vilela p thinkstock istockphoto p lukas beck p printed neue sddeutsche verlagsdruckerei gmbh ulm copyright boehringer ingelheim gmbh rights reserved part annual report may reproduced transmitted form means electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used annual report based data avail able time financial statement drawn upwwwboehringeringelheimcom annualreportboehringeringelheimcomb e h r n g e r n g e l h e annual report value innovationf na n ci l h ig h li g h ts u mm ry r ep r amounts millions eur unless otherwise indicated change net sales region europe americas asia australia africa business prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales research development personnel costs average number employees operating income operating income net sales income taxes income taxes net sales shareholders equity return shareholders equity cash flow investments tangible assets depreciation tangible assets top products top products prescription medicines consumer health care net sales eur million change net sales eur million change spiriva dulcolax pradaxa buscopan micardis mucosolvan trajenta jentadueto pharmaton ove rv iew company shareholders perspective key aspects highlights medicine group management report consolidated financial statements product portfolio c n e n company product portfolio shareholders perspective branded prescription medicines key aspects respiratory diseases corporate bodies cardiovascular diseases highlights medicine metabolic diseases oncology group diseases central nervous system management report infectious diseases information group companies report economic position consumer health care report postbalance sheet date events cough cold risk report sore throat report expected developments pain gastrointestinal diseases consolidated vitamins supplements financial statements leg vein health urological diseases overview major consolidated companies consolidated balance sheet animal health consolidated profit loss statement food producing animals swine cash flow statement food producing animals poultry statement changes group equity food producing animals cattle notes consolidated companion animals horse financial tatements companion animals small animals auditors report u r c p n boehringer ingelheim group one worlds leading pharmaceutical companies headquartered ingelheim germany boehringer ingelheim operates globally affiliates total employees focus familyowned company founded researching developing manu facturing marketing new medications high therapeutic value human veterinary medicine social responsibility important element corporate culture boehringer ingelheim includes worldwide involvement social projects initiative making health caring employees respect equal opportunities reconciliation work family life form foundation mutual cooperation every thing company focuses environmental protection sustainability shareholders perspective boehringer ingelheim christian boehringer chairman shareholders committee h e h r e h l e r p e r p e c v e look back year history boehringer ingelheim becomes apparent changes undergone transition small factory manufacturing tartaric acid niederingelheim germany starting employees international researchdriven pharmaceutical company departure traditional business areas baking powder recently us generics business establishing new segments biopharmaceutical shareholders perspective boehringer ingelheim production least increasing employee numbers around globally today remains important us much ever innovation innovation makes possible create added value make difference new effective medicines human pharmaceuticals animal health well provide prescriptionfree medications best formulations shareholder family see primary responsibility create envi ronment innovation possible know innovations industry happen overnight average takes ten years develop new dicine initial research idea put market market launch depending country might another ten years left patent prescription medicine expires plan provide reliable financial framework long term today important ever given upheaval global pharmaceuticals market increasingly ageing population financed social insurance contributions ever fewer young people leading serious changes healthcare systems changes taking place rapidly researchdriven pharmaceutical company need innovation levels order actively shape upheaval therefore necessary ques tion traditional methods find new solutions researchdriven pharmaceutical industrys contribution becomes obvious regard increase life expectancy also regard fact live ever longer healthy years equally increase markedly since founded one biggest strengths familyowned company ability adapt thus maintain longterm independence year announced initiated concluded numerous changes order maintain competitiveness future want concentrate busi nesses take leading position business must certain critical mass case generics business usa context decided summer sell roxane us business months later announced entering exclusive negotiations sanofi regard strategic swap overthecounter otc medicines business sanofis animal health business result exchange companies would become leading competitors two different disciplines international pharmaceuticals market shareholders perspective boehringer ingelheim part longterm strategy shareholder family also involves discussing agreeing changes board managing directors way cons id er ate careful plannable dr andreas neumann filling standalone human resources position want emphasise significance f unction take future requirements account longterm inter national staff development planning creation separate innovation depart ment dr michel pairet helm also commitment research deve lopment important medicines added value succession procedure set mid regard chairman board managing directors also decision directed towards ensuring contin uity futureoriented outlook hubertus von baumbach successor professor andreas barner well prepared challenges facing company knowledge companys various business areas experience member board managing directors together colleagues drive forward transformation boehringer ingelheim order strengthen paramount goal maintaining independence company long term people boehringer ingelheim bring innovation new management position human resources taking human factor account view adapting longterm international staff development planning orient towards future requirements involves increasing focus corporate culture particularly impor tant times change culture boehringer ingelheim always defined openness mutual esteem empathy trust respect passion importance humaneness company first emphasised ernst boehringer younger son companys founder human intellect take priority intellect must complemented heart brain alone bring human closeness shareholders perspective boehringer ingelheim shareholder family want thank every employee boehringer ingelheim work carried efforts wealth ideas courage always face new challenges least readiness strike new directions offer many opportunities take forward topic innovation boehringer ingelheim independent familyowned company want continue make progress together benefit patients signed christian boehringer chairman shareholders committee key aspects boehringer ingelheim andreas barner wolfgang baiker hubertus von baumbach joachim hasenmaier michel pairet allan hillgrove andreas neumann left right board managing directors k e p e c eventful year boehringer ingelheim medicalresearch business perspective looking back year company recorded submissions approvals product launches ever year history successes also reflected significant growth major strategic decisions also set course past year longterm growth key aspects boehringer ingelheim boehringer ingelheim wellbeing patients animals central field human pharmaceuticals animal health aim develop new effective medicines diseases high unmet medical need new treatment options innovation prerequisite sustainable growth successes past financial year speak regard however market environment becoming ever challenging entire pharmaceutical industry al though global pharmaceuticals market continues grow market access innovative medicines proving increasingly difficult time price pressure continues rise many countries key markets usa japan europe feeling impact predominantly prescription medicines important business despite succeeded expected moderate singledigit growth local currency terms achieving total net sales around billion euros biggest sales contributors remained respiratory medicine spiriva anticoagulant pradaxa micardis used treat high blood pressure achieved sales one billion euros diabetes medicines trajenta jardiance another major growth driver ofev product used patients idiopathic pulmonary fibrosis ipf innovative medicines human pharmaceuticals animal health products also determine growth company success future robust investment planning international research development major element consider investment eleven billion euros international research development human pharmaceuticals next five years alone right approach five billion euros go preclinical research billion euros collaborations external partners research teams currently working total different projects schwerpunkte boehringer ingelheim one outstanding example success research clinical trials new diabetes medicine jardiance firstever diabetes medicine able reduce number deaths due cardiovascular disease specially designed clinical trial another milestone praxbind specific reversal agent oral anticoagulant pradaxa developed also successful year respiratory medicines portfolio spiriva respimat received approval us food drug adminis tration fda indication asthma well new chronic obstructive pulmo nary disease copd medicine spiolto approved use several eu countries well usa start last year european commis sion also issued authorisation ofev used treatment rare respiratory disease idiopathic pulmonary fibrosis pipeline continues promising phase ii trials new biological investigational active ingredient treatment skin condition psoriasis shown improves condition skin quickly longer current gold standard ustekinumab central nervous system therapy area delighted excellent progress made clinical testing several substances treatment schizophrenia alzheimers disease another example new medicine combat specific type lung cancer designated us drug authority fda breakthrough therapy assume pharmaceuticals market continue change rapidly makes important therefore retain scope growth innovation continue successful market future includes focusing core competencies areas business already play leading role globally potential become global leader schwerpunkte boehringer ingelheim able make headway major strategic decisions including sale roxane us generics business end year announce ment entering exclusive negotiations sanofi regarding exchange overthecounter otc medicines business sanofis animal health business would mean boehringer ingelheim would part ways traditional otc medicines business convinced new stronger animal health business would exceptionally well placed growth thereby make us one leading global companies step easy deci sion despite evident marked consolidation market segments however certain otc part boehringer ingelheim make possible sanofi climb world number one business another important step future decision invest half billion euros expansion biopharmaceutical production facilities pioneer field years experience company produced biopharmaceutical medicines worldwide establish new largescale biopharmaceutical production facility vienna austria future production active substances made using cell cultures thus take account future requirements production capacities contract manufacturing inhouse biopharmaceuticals addition expanding production pocketsized inhaler respimat respiratory medicines portfolio ingelheim dortmund facilities germany research development pipeline wellstocked new research strategy implemented ensure longterm innovation performance mediumterm current product launches expansion business activities emerging markets strengthen growth across business areas key aspects boehringer ingelheim across activities company build global workforce around committed motivated employees know innovative strength success boehringer ingelheim fundamentally knowledge experience commitment expertise would like thank employees outstanding performance exceptional team spirit signed signed andreas barner wolfgang baiker signed signed hubertus von baumbach joachim hasenmaier signed signed allan hillgrove andreas neumann signed michel pairet corporate bodies boehringer ingelheim co r p r e bo e shareholders committee board managing directors christian boehringer prof dr dr andreas barner chairman shareholders committee chairman board corporate board division human christoph boehringer resources corporate board division research erich von baumbach jr development medicine isabel boehringer dr wolfgang baiker corporate board divisions biopharmaceuticals dr mathias boehringer operations hubertus von baumbach corporate board division finance advisory board dr joachim hasenmaier egbert appel corporate board divisions animal health chairman advisory board consumer health care trustee martin hilti family trust president hilti foundation allan hillgrove corporate board division kurt beck pharma marketing sales former ministerpresident dr andreas neumann dr andreas kreimeyer corporate board division human resources former member board executive directors research executive director basf se dr michel pairet corporate board division research jan rinnert nonclinical development chairman board management heraeus holding gmbh highlights medicine boehringer ingelheim progress patients medical milestones boehringer ingelheim continues long tradition commit kidney disease compared placebo reduced clinically ting resources create value innovation relevant renal events third data advance public health significant progress measured extensively discussed regulatory authorities diabetes patients see feel value advance specialists worldwide treatments due innovation two highlights value approval praxbind us europe high innovation empareg outcome study lights another research development innovation approval praxbind important patients atrial fibrillation approval half people living type diabetes praxbind means pradaxa blood thinning agent eventually die cardiovascular complications many indicated prevention stroke patients atrial patients significant reduction life fibrillation specific reversal agent praxbind pro expectancy much twelve years september vides physicians additional tool reversal main results large cardiovascular outcomes trial anticoagulant effects pradaxa needed rare empareg outcome publicly shared major dia situations emergency surgeryurgent procedures life betes congress empagliflozin jardiance compound threatening uncontrolled bleeding approval p raxbind treatment type diabetes reduced risk dying based data healthy volunteers well results cardiovascular causes third interim analysis realworld reverse ad patient study clinical trial results empareg outcome reverse ad study data simultaneously published study subsequently presented showed new england journal medicine presented major cardiovascular effect empagliflozin also seen high international congress june boehringer ingelheim risk patients already suffering heart failure renal committed making praxbind available widely possi impairment beginning study additional data ble worldwide continuing obtain regulatory approval empareg outcome presented late suggested countries pradaxa licensed drug also significantly slowed progression diabetic highlights medicine boehringer ingelheim cardiovascular advancing anticoagulation care regulatory authorities us europe commitment innovative care area acute stroke treatment approved praxbind idarucizumab patients risk devastating blood clots actilyse approved specific reversal agent boehringer ingelheim continues evolve treatment acute ischaemic stroke pradaxa dabigatran etexilate anticoagulant landscape boehringer ingelheim launched boehringer ingelheim began research enrolment first patients angels initiative initiative pro praxbind first recircuit recover dvtpe vide doctors tools resources approval pradaxa stroke preven studies latest indication treat support required set stroke net tion atrial fibrillation occurred ment prevention recurrence works improve treatment acute inhouse development deep vein thrombosis dvt pulmo ischaemic stroke thereby advancing pradaxa reversal agent p raxbind nary embolism pe pradaxa local stroke care across globe boehringer ingelheim scientists approved countries globally demonstrates companys continued respiratory important year boehringer ingelheim proud safety nintedanib also investi chance manage symptoms better heritage respiratory disease gated phase iii trial patients early stages disease another important year ofev nintedanib systemic sclerosis another rare life could allow patients remain active received approval eu japan threatening disease longer time treatment patients idiopathic chronic obstructive pulmonary one year first approval pulmonary fibrosis ipf ipf rare disease copd progressive lung dis europe spiriva respimat avail severely debilitating fatal lung disease ease copd predicted able use asthma coun characterised lung tissue scarring third leading cause death globally tries including us extensive clini causing loss oxygen transfer spiolto respimat tiotropiumolo cal evidence reflected inclusion blood ofev slow disease progres daterol launched spiriva respimat latest version sion significantly available treatment patients copd piolto global initiative asthma gina many countries recom built tiotropium active ingredi report mended updated international ipf ent spiriva studies demonstrate treatment guidelines efficacy spiolto respimat offers patients highlights medicine boehringer ingelheim oncology huge unmet needs lung cancer boehringer ingelheim continued efforts two comparator treatments giotrif vargatef improving cancer treatment particularly patients nintedanib another lung cancer treatment patients suffering lung cancer two headtohead trials adenocarcinoma lung provide foun comparing afatinib giotrifgilotrif estab dation boehringer ingelheims lung cancer portfolio lished agents strengthened profile several compounds advanced first approved treatment lung cancer squamous development lung cancer example global piv cell carcinoma lung afatinib showed positive otal trial programme underway bi survival data resulted regulatory submissions could treatment option patients whose us fda european ema new lung cancer progresses egfr tki treatment indication afatinib already approved patients boehringer ingelheim aims achieve first approvals specific types egfr mutationpositive non compound beyond lung cancer small cell lung cancer indication drug boehringer ingelheims strategy aimed develop demonstrated delayed tumour progression compared ing innovative treatment options patients gefitinib another egfr specific treatment lung haematological cancer developing innovative cancer trials afatinib tolerable immunooncology treatments metabolic diseases growing portfolio across diabetes stages addition results empareg outcome treatment needs complex condition well overall diabetes portfolio grew significantly underway beyond empareg outcome together alliance partner eli lilly com jardiance two large cardiovascular outcome trials pany launched six different diabetes carolina carmelina trajenta products major geographies addition trajenta track complete time linagliptin jentadueto linagliptinmetformin treatment diabetes requires holistic jardiance empagliflozin approach beyond medications boehringer ingelheim launched combination drugs glyxambi linagliptin conducting introdia worlds largest empagliflozin synjardy empagliflozinmetformin survey better understand early conversations first biosimilar insulin approved physicians patients type diabe europe new insulin glargine product abasaglar tes patient data survey pre launched several european countries well sented late serve basis japan develop solutions improve early conversations clinical trials regulatory submis type diabetes sions combination tablets meeting individual highlights medicine boehringer ingelheim central nervous ystem cns mysteries human brain boehringer ingelheim concentrating development one pde never solution illnesses like identifying brain chemistry responsible inhibitor phase ii study alzheimers schizophrenia common debili boehringer ingelheim also includes addition pharmacological treatment tating symptoms across range brain research activities fields psy supporting therapies sensible diseases including schizophrenia chiatry including treatmentresistant necessary explains dr jrgen ree alzheimers disease treatmentresis depression compounds investi therapeutic area head cns accord tant depression one major symptom gation designed increase brains ingly also employ elements like cog cognitive impairment meaning reduced neuroplasticity allowing nitive performance training context mental ability concentrate think learn form new connections nerve studies investigate whether memorise leads signifi cells way hoped cog positive effects individual cant problems social life everyday nitive impairments could normalised treatment elements boosted functioning therapeutic area cns boehringer ingelheim plans pres used combination truly innovative wellstocked pipeline including ent first phase ii results approach industry couple molecules early stage clinical recognise medication alone immunology successes immunology research past year also shown innovation months nearly triple percentage bi investigated immunology boehringer ingelheims patients risankizumab compared several diseases immunology abbvie frontrunner biologic ilp ustekinumab long standing heritage immunol blocker anticipated substance light current high potential ogy partnering abbvie best name risankizumab demonstrated risankizumab second frontrun way ensure medicines reach phase ii trial nine months ner molecule boehringer ingelheim right people achieve full potential per cent patients moderateto immunology pipeline maximising boehringer ingelheim severe plaque psoriasis maintained number patients around world involved research development clear almost clear skin pasi access promising immunology space many years risankizumab higher dose group potential treatment approved continue invest research compared per cent patients critical public health perspective development earlier phase ustekinumab patients also achieved boehringer ingelheim therefore en compounds immunology pipeline skin clearance significantly faster tered agreement form global proactively building pipeline two months longer collaboration abbvie bring capabilities important area ustekinumab completely clear skin ward two advanced investiga pasi maintained nine tional compounds risankizumab group management report boehringer ingelheim group management report g r u p n age e n r e p r information group companies report economic position report postbalance sheet date events risk report report expected developments konzernlagebericht grundlagen des konzerns group management report information group compani es boehringer ingelheim information group companies group management report information group companies groups business model boehringer ingelheim promising product authorisations boehringer ingelheim familyowned company obtained ofev offers people established based ingelheim rare fatal respiratory disease idiopathic pulmonary germany focus company research fibrosis ipf new treatment option praxbind development production sale innovative antidote anticoagulant pradaxa revokes pharmaceuticals improving health quality effects within minutes intake life contributing great therapeutic b enefit human animal health affiliated business aim boehringer ingelheim drive companies around employees worldwide forward innovative development existing group achieved net sales eur billion product portfolio organic growth also cooper making one worlds top pharmaceutical companies boehringer ingelheims business activities cover prescription medicines consumer health care net sales business eur million animal health biopharmaceuticals industrial cus tomers prescription medicines prescription medicines form core companys activities medicines boehringer ingelheim long standard treatments respiratory disorders consumer health care cardiovascular disease metabolic disease oncology diseases central nervous system com panys biggest revenue contributor spiriva used treat chronic obstructive pul animal health monary disease copd also approved use asthma patients pradaxa used prevent strokes patients atrial fibrillation well prevention treatment thromboembolic biopharmaceuticals disorders micardis well estab lished years used treatment hypertension make sig nificant contribution companys success trajenta jardiance industrial customers sales impressive trajectory used treat type diabetes also supporting positive growth group management report net sales region eur million australia africa aaa also gaining significance group making groups total net sales three biggest markets usa japan germany accounted around sales last year research development rd line boehringer ingelheims mission statement europe primary goal research develop innovative medicines therapies treatment diseases asia yet satisfactory treatments available australia africa aim times make major contribution americas aaa areas need treatment high occupy leading position major indication areas achieve aim addition research ation external partners boehringer development teams boehringer ingelheim draw ingelheim operates global research network global network comprising academic groups biotech companies addition expanding product within consumer health care dulcolax buscopan portfolio partnership agreements systematic mucosolvan pharmaton among com inlicensing technologies products year panys highest selling medicines review example boehringer ingelheim con cluded licensing agreement korean company animal health another major pillar boehringer hanmi pharmaceutical development targeted ingelheims business pig vaccine ingelvac circoflex therapy lung cancer patients certain epidermal used treat porcine circovirus type signifi growth factor receptor egfr mutations cant product animal health terms sales boost boehringer ingelheims competitiveness animal boehringer ingelheims research development health area long term company entered exclu activities basis companys success together sive negotiations french company sanofi sa generally innovative prowess december aim trading sanofis animal primary driver behind groups positive growth health business boehringer ingelheims consumer recent years inhouse research development also health care business parties counting continue top priority future example transaction finalised towards end consistent implementation strategy research facility vienna austria inaugu biopharmaceuticals business comprises manufacture rated november oncological research takes place ownbrand marketable products development lab facility order open new therapy options biosimilars one worlds leading companies doctors help people tumours investments process development contract manufacturing facility amounted around eur million commercial production thirdparty customers financial year employed average boehringer ingelheim achieved majority people research development sites sales americas europe total around eur billion invested regions however revenue region asia research development new medicines group management report information group compani es boehringer ingelheim research development expenditure eur million net sales prescription medicines expenditure eur million prescription medicines net sales average number employees investments tangible assets without investments infrastructure eur million corresponding groups net sales thus spiolto respimat based tiotropium enhanced also forecast level previous year long acting betaagonist olodaterol large tovito phase iii clinical trial programme investigat human pharmaceuticals ing efficacy safety spiolto respimat boehringer ingelheim carried research develop includes clinical trials patients ment prescription medicines consumer enrolled total health care businesses facilities usa germany austria italy japan last year aboveaverage number new data subgroup analysis pivotal registrations new products obtained sub phase iii tonado studies presented ameri mitted key focus research work thoracic society congress ats denver data following indication areas showed spiolto respimat provided lung function benefit patients copd right start respiratory diseases maintenance therapy greatest benefit shown cardiometabolic diseases cardiovascular metabolic patients moderate copd gold sum diseases mer publication phase iiib otemto oncology trials respiratory medicine provided new data diseases central nervous system showed spiolto respimat offers consistent clinically immunology meaningful improvements quality life versus placebo patients copd expenditure rd prescription medicines accounted net sales generated business landmark year boehringer ingelheim respiratory last years company us brand name stiolto respimat canada inspiolto active field emerged leader lung dis respimat buhl r maltais f abrahams r et al tiotropium olodaterol fixeddose eases last year therapeutic area ta respiratory combination versus monocomponents copd gold eur respir j brought new treatment advances patients apr buhl r abrahams r grnke l et al tiotropium plus olodaterol fixeddose combination therapy provides lung function benefits compared tiotropium alone irrespective prior treatment longacting broncho chronic obstructive pulmonary disease copd spiolto dilator post hoc analyses two year studies ats congress abstract respimat tiotropiumolodaterol received approval singh ferguson gt bolitschek j et al tiotropiumolodaterol shows clini cally meaningful improvements quality life res med doi http us canada japan many european countries dxdoiorgjrmed group management report energito study showed lung function midyear ofev included updated interna improvement spiolto respimat superior tional atsersjrsalat clinical practice guideline inhaled corticosteroid therapy fluticasone propionate treatment idiopathic pulmonary fibrosis salmeterol fixeddose combination fdc patients marked important step forward patient care moderate severe copd committee noted high value ofev patient important outcomes disease progression meas spiriva respimat first new class inhaled asthma ured declining rate forced vitality capacity fvc treatments approved decade one year first approval europe spiriva respimat boehringer ingelheim expanding research available use asthma countries including nintedanib progressive fibrotic lung diseases usa september us food drug one devastating conditions rare disease administration fda approved spiriva respimat systemic sclerosis commonly accompanied pulmonary tiotropium bromide inhalation spray use treat manifestations december senscis safety ment asthma longterm oncedaily maintenance efficacy nintedanib systemic sclerosis phase iii treatment patients years age older study began recruiting patients study include patients systemic sclerosis associated interstitial spiriva softmist inhaler respimat included lung disease addon asthma therapy recent global initia tive asthma gina report global strategy focus boehringer ingelheims research activities asthma management prevention field cardiovascular disorders marked advancement anticoagulation care boehringer ingelheim beginning boehringer ingelheim announced presented first results patient study investigat european commission ec approved ninte ing effect praxbind specific reversal agent danib treatment idiopathic pulmonary fibrosis anticoagulant pradaxa revokes effects within ipf following expedited review positive chmp minutes intake realworld emergency setting committee medicinal products human use interim results ongoing phase iii reverse ad opinion november nintedanib marketed study presented international society throm eu japan usa countries brand bosis haemostasis congress toronto canada june name ofev ipf rare severely debilitating fatal simultaneously published new england journal lung disease ofev boehringer ingelheim medicine praxbind support care p radaxa offering new treatment option patients treated patients emergency situations providing devastating disease physicians additional tool reversal anti coagulant effects pradaxa needed pivotal phase iii inpulsis trials well phase ii tomorrow trial demonstrated ofev indication area metabolic disorders focus consistently slows disease progression patients research development drugs treatment ipf reducing annual decline lung function diabetes results cardiovascular outcomes trial empareg outcome demonstrated jardiance empagli flozin reducing death caused cardiovascular compli beeh km derom e echavesustaeta j et al energito efficacy safety oncedaily combined tiotropium olodaterol versus twicedaily combined cations overall cardiovascular effect jardiance fluticasone propionate salmeterol poster pa ers abstract number also seen high risk patients already suffering group management report information group compani es boehringer ingelheim heart failure renal impairment study beginning incidence adverse events nintedanib boehringer additional data empareg outcome showed ingelheims second approved lung cancer treatment jardiance also significantly slowed progression evaluated indications beyond lung cancer diabetic kidney disease compared placebo saw initiation two registration trials investigating reduced clinically relevant renal events triple angiokinase inhibitor patients advanced third received approval launched colorectal cancer patients malignant pleural combination drugs glyxambi linagliptinempagliflozin mesothelioma synjardy empagliflozinmetformin clinical trials regulatory submissions additional german institute quality efficiency health combination tablets meeting individual treatment care iqwig stepped rating afatinib needs complex condition well underway standing therapeutic benefit based positive overall beyond empareg outcome jardiance two survival data shown comparison chemotherapy large cardio vascular outcome trials carolina two independent trials patients frequent carmelina trajenta schedule complete egfr mutation del nintedanib received positive time evaluations health technology assessment bodies uks national institute health care excel indication area oncology boehringer ingelheim lence nice iqwig successfully advanced research development pipeline compounds marketed treatments approvals giotrif vargatef laid aim providing new treatment options may offer foundation boehringer ingelheims lung cancer port patients added therapeutic value contribute quality folio several compounds advanced develop life improvements ment lung cancer example global pivotal eluxa trial programme underway bi boehringer ingelheim continued efforts could treatment option patients whose lung improving cancer treatment particularly patients cancer progresses egfr tki treatment com suffering lung cancer two head head trials com pound granted breakthrough therapy designa paring afatinib giotrifgilotrif established tion us fda boehringer ingelheim aims agents strengthened profile first approved first approvals compound treatment lung cancer squamous cell carcinoma lung afatinib showed positive survival data beyond lung cancer boehringer ingelheims strategy resulted regulatory submissions us fda aimed developing innovative treatment options ema new indication afatinibs already patients hematological cancer well broadening approved indication egfr mutationpositive nonsmall presence field immunooncology cell lung cancer drug delayed tumour progression comparison gefitinib trials afatinib research team central nervous system cns dis tolerable comparator treatments similar eases boehringer ingelheim focuses identifying inzucchi et al empagliflozin cardiovascular outcomes patients advanced squamous cell carcinoma lung luxlung openlabel type diabetes mellitus high cardiovascular risk scientific randomised controlled phase trial lancet oncology zinman b et al empagliflozin cardiovascular outcomes mortality dois type diabetes n engl j med park k et al afatinib versus gefitinib firstline treatment patients wanner c et al oral presentation empagliflozin cardiovascular advanced nonsmall cell lung cancer harboring activating egfr mutations comes patients type diabetes chronic kidney disease asn results global randomized openlabel phase iib trial luxlung kidney week abstract sapo j soc neph b lba oral presentation esmo asia congress singapore soria et al afatinib versus erlotinib secondline treatment patients december group management report brain malfunctions responsible launched otc ibuprofen therapy japan uniquely important symptoms shared different brain diseases positioned pain relief women schizophrenia alzheimers disease animal health one major symptoms found across diseases research development work field animal cognitive impairment wellstocked cns pipeline health boehringer ingelheim focuses innovative three molecules advanced stage develop vaccines protection livestock pets well ment including pdeinhibitor already pharmaceutical products facilities usa phase ii clinical development germany china mexico japan netherlands focus research new drugs development cns teams confident advance future therapeutic solutions since many vaccines clinical programs next years boehringer based local pathogens pathogen variants ingelheim gets closer new treatment options imperative present key market regions patients diseases local research development production facilities immunology major important results achieved phase ii psoriasis trial boehringer ingelheims past year around eur million invested biologic risankizumab risankizumab ilp expansion existing facilities well con blocker cleared skin better faster longer struction centre clinical research china current gold standard ustekinumab investments demonstrate companys commitment intention sustainably strengthen position nine months patients moderate animal health severe plaque psoriasis maintained clear almost clear skin pasi risankizumab higher dose group first half year eu countries granted compared patients ustekinumab patients authorisation two improved vaccines also achieved skin clearance significantly faster porcine respiratory reproductive syndrome prrs two months longer usteki ingelvac prrsflex eu piglets reprocyc prrs eu numab completely clear skin pasi maintained sows via decentralised process specially devel nine months nearly triple percentage oped vaccines take account different immune patients risankizumab compared ustekinumab reactions adult pigs versus piglets product ingelvac prrsflex eu boehringer ingelheim able boehringer ingelheim investing research offer prrs vaccine european market development range earlier phase compounds specially designed use piglets minimises immunology pipeline indications crohns symptoms respiratory disorders reduces trans disease ulcerative colitis lupus nephritis mission virus used active immu nisation healthy swine age days consumer health care business boehringer ingelheim contrast reprocyc prrs eu used vaccinate successfully launched products mucoangin sore young sows breeding sows affected prrs throat spray dulcosoft europe mucoangin sore phases production regardless whether throat spray contains ambroxol indicated pregnant pain relief acute sore throat whereas dulcosoft gentle laxative japan eve ex also successfully globally boehringer ingelheims animal health business launched year eve product range first received product authorisations group management report information group compani es boehringer ingelheim biopharmaceuticals boehringer ingel heim invested production capacity boehringer ingelheim committed strategic decision respiratory disease products spiriva handihaler actively entering biosimilars business respimat platform meet demands thereby increasing access highquality biologics market patients around world company focuses driving first wave biosimilar compounds immu cover increasing demand antidiabetic nology oncology working molecules portfolio boehringer ingelheim invested around preclinical development pivotal phase iii eur million production facilities mexico city trials bi biosimilar candidate humira koropi greece bi biosimilar candidate avastin initiated programmes well track animal health field animal health boehringer ingelheim production primarily active north central america human pharmaceuticals production network comprising four facilities manu overarching aims production human pharma facturing vaccines one facility nutraceuticals ceuticals reliable market launch products network contract manufacturers pharmaceutical routine care patients using highquality products construction new chinese facility pharmaceuticals taizhou continuing apace asian location soon join production network major end boehringer ingelheim revised supply component animal health growth strategy strategy motto volume value facility focus manufacture vaccines supply network set reorganised next porcine avian diseases chinese market years reflect requirements businesses biopharmaceuticals production facilities focus manufacture biopharmaceutical activities boehringer ingelheim products high relevance group whose germany biberach austria vienna usa manufacturing technology requires specific degree fremont china shanghai comprise manufacture expertise operated production facilities ownbrand marketable products actilyse eleven countries year review metalyse praxbind process development divided eleven pharmaceutical three chemical nbes biosimilars one worlds four biopharmaceutical facilities well one pro leading companies process development contract duction facility medical products manufacturing commercial production thirdparty customers boehringer ingelheim covers production facilities supplemented entire bio pharmaceutical value chain genetic external contract manufacturers primarily focus development cell followed manufacturing manufacture products advanced filling finished pharmaceutical product stage life cycle ensures reliable competitive product launch global market supply compari supply prescription medicines consumer health son previous year saw overall increase care products close cooperation external partners full use capacity production facilities active secures boehringer ingelheim access technologies substance praxbind successfully produced currently available internal production boehringer ingelheim launched american portfolio european markets group management report companys promising biopharmaceutical develop employee protection examined regular audits ment projects strong demand market order continuously identify potential areas contract manufacturing basis decision improvement make significant investments expanding bio pharmaceutical production capacity boehringer ingel extensive work analyse decontaminate soil heim setting new industrialscale biopharma around ingelheim facility germany contin ceutical production facility vienna active sub ued order ensure appropriate protection stances made using cell cultures new environment necessary result techni production facility due go operation cal progress issues analysed also pushed ahead establishing new precisely today experts fields geochemistry facility shanghai various biopharmaceutical develop environmental toxicology engineering consulted ment services chinese international customers advice implementing measures keep pilot facility manufacture biopharmaceutical public date progress clinical trial supplies successfully went production made first deliveries gmp standard clinical trial order make contribution towards reducing global samples customers building co emissions set ambitious house commercial facility completed goal reducing co emissions terms sales expect go operation planned compared values aim putting focus potential energy savings occupational safety environmental reductions emissions promoting exchange protection expertise companys facilities coordi protection employees facilities nating projects international level environment well sustainable use natural resources promotion environmental awareness health safety employees high priority major components companys mission state boehringer ingelheim reflected high ment prime importance boehringer ingelheim global safety standards guidelines well past year boehringer ingelheim implementation safety culture groupwide environment award german federal state safe initiative launched aims fur rhineland palatinate outstanding efforts pro ther reduce number workplace accidents tect environment nature natural resources since rolled almost international facilities compliance social environmental aspects focus global measures human behaviour anchored corporate philosophy many years order achieve ambitious target accident company strives maintain natural resources frequency rate afr less accidents per million advocates environmental awareness within hours worked afr stayed outside company observing social ecological slightly level prior year concerns way ensure enjoy sustainable financial success groupwide company developed binding stand ards terms environmental protection health safety work internal guidelines reflect respec tive countryspecific legal requirements compliance standards status environmental group management report information group companies boehringer ingelheim report economic position employee reporting one companys aims strengthen appeal boehringer ingelheim employed around boehringer ingelheim top employer current people worldwide regional perspective future employees boehringer ingelheim number staff america reduced recipient various awards efforts area number employees europe aaa including named one innovative region increased companies world news agency thomson reu ters award proof pioneering approach average number employees region longterm strategy boehringer ingelheims hr work americas addition company received top rating europe around students survey conducted asiaaustraliaafrica aaa international research consulting firm universum aimed identifying popular german employers every year boehringer ingelheim enables major success factor positive growth around trainees obtain practical work experience group innovative dedicated reliable staff variety areas within company past accordingly committed actively devel oping year company received highest rating employer supporting employees order best pre quality pharmaceuticals industry prakti pared challenges ahead part comprehensive kantenspiegel trainee satisfaction survey training system set great store one biggest employer branding studies germany acquisition technical expertise also promoting social skills boehringer ingelheim also named employer year germany austria china addition competitive salaries boehringer ingelheim received top marks auditors international offers benefits employees benefits independent top employers institute major hr include company pension plans flexible homebased categories talent strategy staff planning work options countless healthrelated benefits well performance management onboarding significant segment corporate strategy part evidence high appeal development talent management departments remit ensure opportunities company employees employability staff promote wide range potential recruits opportunities innovation work motivate employees nurture talents develop social responsibility individuals taking social responsibility also important aspect corporate culture commitment wellbeing vocational training always major importance patients employees families focus boehringer ingelheim part understanding range projects addition support people social responsibility company offers career oppor need various initiatives particularly countries tunities great number young people regions active company time also tie talented wellqualified workforce companys activities also focus protecting main young professionals company back taining environment drop demographic change young profes sionals started careers boehringer ingelheim addition longterm initiatives boehringer ingel germany different scientific technical heim also provides help urgently needed commercial fields example boehringer ingelheim helping asylum group management report seekers germany gifts donations area diversity markets reflected work accomodation facilities refugee reception center force creating working environment embraces provided well food supply boehringer ingelheim diversity differences one pillars also involved integration refugees interested corporate culture boehringer ingelheim con parties invited take tours facility tributing factor companys success introduced various businesses given presentation german apprenticeship sys boehringer ingelheim involved tem furthermore refugees already integrated herzenssache schlaganfall taking stroke heart apprenticeships form oneyear awarenessraising initiative last year campaign introductory training programme named best national patient information campaign received health media award initia major pillar social commitment making tive launched boehringer ingelheim health mmh initiative five years boehringer promotes projects raise awareness atrial ingelheim partnership ashoka global fibrillation associated risk stroke well nonprofit organisation aim partnership improving public perception independent organi integrate health major factor peoples lives around sations around world involved world including families social envi initiative awarenessraising events carried ronment aims identify support promising cities part initiative ideas improving health order achieve supported deutsche gesellschaft fr kardiologie making health currently promotes german cardiac society dgk selected social entrepreneurs around world attempting come effective solutions boehringer ingelheim continues actively support healthcare sector research science culture longterm partnerships academic institutions serve underline companys social commitment within company also encour systematic focus research development since aged boehringer ingelheim employees example boehringer ingelheim invested countries work mmh initiative research projects investigating infections porcine mmh youth venture project entrepreneurial skills circovirus type pcv associated diseases developed working together designing social pro addition supporting sponsoring scientific activities jects actively supported mentors workforce scientists also awarded annual boehringer initiative supported executive residence ingelheim fens research award neuroscience eir mmh insight india staff development pro heinrich wieland prize research biologically grammes programme gives young managers active substances systems opportunity support social entrepreneurs health care sector project facilities specific period time develop promote socially aware report economic approach business position integration various experiences cultural backgrounds personalities boehringer ingelheim macroeconomic environment creates openness different approaches opinions global economy expanded rate living motto value innovation moderate growth primarily due weak devel global company important boehringer ingelheim opment emerging economies slowdown group management report report economic position boehringer ingelheim chinese economy decrease global demand measured consumer price index one commodities detrimental impact main reasons decrease oil prices growth emerging economies compared previous year contrast cost services food rent increased rate inflation major industrialised countries economic situa whole eurozone thus also lower tion showed clear upturn course previous year supported particular continued positive growth usa uk economic situation addition euro major currencies eurozone also showed improvements stimulated boehringer ingelheim group us dollar usd expansive monetary policy european central japanese yen jpy euro continued gener bank increased purchasing power private house ally weak course following last years holds contrast economic growth japan moder phase sharp devaluation first quarter ate impetus monetary fiscal euro fluctuated within relatively narrow range policy decisions previous year lost effect compared two currencies relation us dollar rate varied usd eur growth still forecast global economy april usd eur january compared expect see continued stable development japanese yen euro varied jpy eur usa uk furthermore economic april jpy eur january growth eurozone looks set continue gradual slowdown china likely related close economic global pharmaceuticals market registered growth ties emerging economies dampening around financial year growth effect according experts lead driven increasing demand innovative medi slowing growth countries cines increased access medicines patients emerging economies particularly positive economic development continued noticeable rise demand generics otc medi germany economic output upturn cines industrialised countries market supported primarily positive development depressed health policy measures price regulation labour market increased purchasing power private well increased cost pressure health care sys households rise private consumption addi tems patented pharmaceuticals particular experienced tion regressive interest rates also improved conditions radical changes market environment investments despite rather restrained growth world trade exports grew supported course business continually weak euro secure boehringer ingelheims independence long term strategic focus sustainable long view assume positive eco term competitive development company well nomic growth germany continue forecast stable earnings sound financing previous years growth around stronger expansion ger based approach principles year man economy hindered predicted shrinkage review emerging economies associated lower demand german capital goods another challenging year boehringer ingelheim exceptionally eventful year company average rate inflation prices able record submissions approvals prod germany decreased compared previous year uct launches ever year history one group management report outstanding example success research americas region achieved sales growth development new diabetes medicine jardiance compared previous year sales whose active substance regulates blood sugar eur million around total sales level also firstever diabetes medicine able americas region remains biggest sales market reduce number deaths due cardiovascular dis boehringer ingelheim eurodollar exchange rate ease people type diabetes specially designed positive impact revenue situation year trial approval praxbind antidote review adjusted currency effects increase sales anticoagulant pradaxa revokes effects within amounted strong growth recorded minutes intake europe usa another asiaaustraliaafrica aaa region major milestone boehringer ingelheim addition adjusted currency effects boehringer ingel product ofev offers people rare fatal heim achieved revenues eur million respiratory disease ipf new treatment option region corresponding stable share around improves life expectancy received market approval groups total revenues europe region showed spiolto improves already posi low sales growth eur million tive therapy results spiriva treatment meant almost groups sales made copd product spiriva respimat received addi region tional authorisation us food drug adminis net sales region currency tration fda use patients asthma eur million change adjusted also year heralded implementation major americas strategic decisions aiming help us remain successful europe market future focus areas busi asiaaustraliaafrica ness already play leading role globally aaa could become global leader us business gener ics sold company hikma pharmaceuticals general sales growth conformed expectations plc following signing agreement com supported good results clinical trials pany effect july assume transfer able launch promising new products success ownership go ahead first quarter fully push ahead wellestablished products addition entered exclusive negotiations hand experiencing increasingly difficult french company sanofi sa december market situation constantly challenging market access aim trading sanofis animal health business growing price pressure key markets usa boehringer ingelheims consumer health care business japan europe overall company asserted parties counting transaction final well despite difficult conditions laid foun ised towards end dations growth boehringer ingelheim recorded sales eur mil boehringer ingelheim recorded operating result lion financial year corresponds eur million corresponding return sales increase compared previous years percentage points previous value eur million exchange rate develop year 's return sales hand operating ments foreign exchange markets associated result increased absolute terms eur million exchange rate effects positive impact currency ad confirming expectations increase justed boehringer ingelheims growth rate stood sales costefficiency measures introduced positive effects group management report report economic position boehringer ingelheim eur million also corresponds key figures eur million change increase level net sales operating income micardis medicine used treat high blood pres return net sales sure achieved sales eur million results operations last year expected decline resulted boehringer ingelheims business activities divided loss exclusivity additional markets prescription medicines consumer health care animal net sales eur million change health biopharmaceuticals industrial customers spiriva net sales businesses currency pradaxa eur million change adjusted micardis prescription medicines trajenta jentadueto consumer health care animal health regard regional distribution sales biopharmaceuticals americas share far industrial customers sales largest market region boehringer ingelheim generated net sales eur million corre prescription medicines sponds change compared previ around total revenue prescription medicines ous year currency adjusted sales perfor main pillar boehringer ingelheims business mance important market americas activities revenues prescription medicines usa greatest impact development amounted eur million including previous sales eur million addition positive years sales generics usa equivalent growth favourable exchange rate developments major change around currency adjusted contributors increase revenues came compared previous year positive sales growth currency adjusted due successful launch numerous new products good results clinical trials experiencing secondbiggest market europe accounted increasing price pressure however particularly estab revenues eur million sales thus remained lished medicines number major markets overall steady compared eur million boehringer ingelheim able assert well subject significant exchange rate effects reve difficult environment laid foundations nues germany france particular lower growth previous year net sales region previous years spiriva used treat eur million change chronic obstructive pulmonary disease copd americas biggest contributor sales europe achieved revenues eur million within asiaaustraliaafrica aaa reporting period thus level previous year eur million aaa region achieved sales eur million second biggest sales contributor boehringer equivalent total sales prescription ingelheim anticoagulant pradaxa recorded sales medicines region showed increase group management report compared last year currency adjusted sales americas region third largest sales market eur million recorded japan biggest consumer health care business ended financial year sales market boehringer ingelheim region cor slight decline revenues currency responding change compared pre adjusted compared previous year achieving total vious year sales eur million consumer health care animal health consumer health care sales increased com revenues products animal health business pared previous year currencyadjusted increased eur million corresponding business boehringer ingelheim generated revenue increase previous year currency amounting eur million adjusted sales products livestock accounted largest share eur million corresponding biggest sales contributors consumer around entire animal health segment health care segment dulcolax buscopan previous year biggest sales contributor mucosolvan pharmaton zantac products swine vaccine ingelvac circoflex accounting generated revenue significantly eur mil eur million pet segment revenues amounted lion result positive growth ulcolax eur million biggest seller sales eur million net sales eur million change buscopan showed slight increase ingelvac circoflex generated sales eur million positive results metacam also achieved mucosolvan sales increasing ingelvac prrs eur million duramune net sales eur million change dulcolax growth animal health segment sig buscopan nificant americas region accounting mucosolvan total sales biggest sales market boehringer pharmaton ingelheim business grew currency adjusted eur million us market par regions europe generated highest sales ticular sales increased eur million eur million corresponds share global sales consumer health care business boehringer ingelheim also saw revenues grow europe sales last year boehringer increasing eur million rise ingelheims key european market germany revenues currency adjusted accounting increased total revenues animal health business sales germany slightly previous year 's level aaa region ended financial year sales sales uk experienced particularly positive growth amounting eur million increase compared previous year currency adjusted region therefore accounted increase currency adjusted boehringer ingelheims consumer health care business aaa region also recorded positive growth compared previous year recording sales eur mil lion china particular able achieve impressive group management report report economic position boehringer ingelheim growth net sales amounting holding income increased eur million eur eur million million und contains income dismissal related companies biopharmaceuticals sales biopharmaceutical contract manufac income taxes developed line result turing amounted eur million represents operating activities increasing eur mil growth compared previous year lion tax expenses amounted eur million must noted regard provisions industrial customers sales german commercial law shareholders personal taxes industrial customer business consists third arising group business activities may recog party businesses field pharmaceutical chemi nised tax expenses instead taxes presented cal production contract manufacturing business part withdrawals group equity taking pharma chemicals sales eur million extraordinary effect account actual tax ratio achieved corresponding decrease revenue markedly higher figure shown profit currency adjusted compared loss statement previous year financial year net income presentation expenditure income boehringer ingelheim group totalled eur mil operating expenses boehringer ingelheim increased lion corresponding increase eur million eur million financial year represent previous years level eur million ing rise compared previous year mate rial costs higher previous year com financial position ing eur million making boehringer ingelheims financial management instru total sales personnel costs amounted ments methods aimed securing liquidity mini eur million corresponding personnel mising financial economic risks optimising cost ratio slightly lower cost capital appropriate capital structure previous year financial activities therefore geared towards support ing business strategy depreciation recorded increase eur million eur million operating expenses global company exchange rate volatility significant rose compared previous year coming impact boehringer ingelheims financial performance eur million among items cost importance us business associated block includes commission licence payments supply relationships mean exchange rate develop dependent sales ment us dollar constitutes greatest individual risk within framework groupwide financial operating result slightly higher predicted reporting foreign exchange risk calculated hedged eur million previous derivative financial instruments nature year eur million scope measures set group guidelines regularly discussed approved relevant reporting period financial result amounted committee standardised process eur million eur million compared previous year largely due increased investments great importance boehringer ingel interest expense pensions similar obligations heim strategic point view continuous investment group management report requirement longterm success develop cash flow led increase liquidity eur ment company forms basis profita million ble growth business divisions net assets total eur million invested tangible financial year boehringer ingelheims total intangible assets year review assets amounted eur million increase eur million compared years boehringer ingelheim previous year tangible intangible assets totalled investing around eur million expansion eur million fully covered consoli production capacity respimat inhaler dated equity dortmund ingelheim facilities germany boehringer ingelheim microparts gmbh dortmund manufactures end year financial investments amounted respimat inhalation system filled eur million corresponds increase relevant active substances pharma ceutical eur million previous years value inventories production facility ingelheim ready global sales showed growth eur million trade receivables rose eur million eur million addition new bi administrative office liquid funds including securities within current augurated ingelheim facility november assets stood eur million eur million representing investment around eur million alltogether underlines strategic role signi due aforementioned changes cash cash ficance location group equivalents group equity amounted eur mil lion addition equity pension provisions boehringer ingelheim invested longterm liabilities also available group significant growth market china group plans long term total three items amounted invest around eur million expansion eur million representing share manufacturing facilities chemical research total assets consequently longterm disposable development laboratory shanghai next five capital covers intangible tangible assets invento years research development fields human ries trade receivables animal medicines remain top priority boehringer ingelheim reflected investments provisions around higher last made research facilities germany austria year eur million liabilities increased margin usa ally eur million previous year cash flow amounted eur million cash status already shown financial position flow operating activities increased eur mil remains resoundingly positive balance sheet lion previous years meant investments respective balance sheet ratios sum could financed entirely funds generated boehringer ingelheims net assets financial earnings company total eur million invested position confirm credentials soundly financed tangible assets without consideration subsidies profitable company eur million intangible assets terms cash flow financing activities recorded outflow funds amounting eur million overall changes group management report report postbalance sheet date events boehringer ingelheim risk report report postbalance persons responsible key businesses sheet date events functions included process calculating assessing risks groupwide risk information system ensures identified risks analysed boehringer ingelheim signed assessed carefully following appropriate classifi agreement development commercialisation two cation various categories adequate countermeasures products belonging therapeutic area immunology initiated implementation consistently significant income related transaction monitored impact financial year closing transaction subject conditions defined year review internal auditing performed agreement targeted routine audits well extraordinary audits around world addition adherence legal since end financial year requirements internal group guidelines main become aware events material focal points functionality systems significance group companies could lead effectiveness internal controls prevention reappraisal net assets financial position loss assets efficiency structures results operations processes corresponding adjustments optimisations initiated necessary risk report individual risks important risks boehringer ingel risk opportunity management heim exposed broken following aim risk management system implemented specific categories financial risks legal risks production boehringer ingelheim identify businessspecific risks environmental risks personnel risks sector particular risks jeopardise continued specific risks existence company early possible assess reduce reasonable level means risks identified concrete suitable measures appear controllable means specific manage ment procedures term abstract used case assessing risks context holistic risk risks completely controlled even management also endeavour take account means targeted management procedures regardless resulting opportunities opportunity management based probability occurrence strategies objectives company individual businesses operating business units integral financial risks part groupwide planning management systems relevant financial risks broken responsible businesses functions bear follows currency risks credit countryspecific risks direct responsibility early systematic identifica well management financial investment risks tion analysis use opportunities boehringer ingelheim researchdriven innovative pharma currency risks ceutical company c urrent research development global orientation business activities results activities naturally considered relevant opportunity currency risks due exchange rate volatility particularly detailed description projects illustrated regard us dollar japanese yen group research development chapter monitors quantifies risks regular intervals group management report making predictable future business means currently product liability insurance companys relevant hedging strategies appropriate financial risk profile absolutely guarantee however instruments forward exchange contracts insurance coverage maintained reasonable resultant risks subsequently designated cost acceptable conditions sufficient concrete therefore controllable protect boehringer ingelheim claim loss potential claims losses credit countryspecific risks boehringer ingelheim exposed various credit furthermore product liability claims could tie sub countryspecific risks result international business stantial financial resources management capacity activities portfolio trade accounts receivable detrimental companys image event trade accounts payable identified market considers product unsafe ineffective extraordinary risks group beyond usual level result unexpected side effects boehringer ingel sector applies possible default risks heim closely monitors products development receivables largely hedged economic well market attributes particular impor political risks continue carefully track tance benefitrisk ratio regular assessment credit countryspecific risks position regard risk abstract respond negative changes timely manner risks therefore regarded concrete patent protection risks protection innovations trademark brand management financial investment risks patent rights particular importance boehringer group pursues defensive investment strategy ingelheim research company commercial pro management financial assets reflected tective rights increasingly target attacks orientation portfolio focused european breaches taken necessary precautions economic monetary union emu government bonds allow us detect threats early stage com top credit ratings shortterm investments mencing appropriate countermeasures defend legal various banks results concrete thus position using legal means available us controllable risk risks regarded concrete legal risks production environmental risks business activities group exposed legal quality management system compliance pro risks distinction made regulatory liability cesses optimised close cooperation patent protection risks relevant authorities order ensure compliance cgmp standards current good manufacturing practice regulatory risks future risks area continue high signifi boehringer ingelheim exposed risks arising legal cance group classified abstract disputes proceedings well official investigations legal administrative decisions ongoing future order guarantee supply products proceedings predicted regard resultant market implemented measures guarantee risks abstract reliable highquality supplies internal external customers addition supplier management liability risks procurement side also involves building internal marketing sale pharmaceuticals exposed standby capacities result see risk concrete potential product liability risk boehringer ingelheim group management report risk report boehringer ingelheim report expected developments risks areas environment health safety therefore keeping close eye various changes sustainability ehss preemptively minimised sales markets already started respond ensuring global adherence high safety standards current developments costsaving efficiency appropriate emergency plans drawn improving measures initiated possible incidents kind practised subjected comprehensive quality testing regular overall statement risk situation intervals result measures risks current perspective aware risks classed concrete alone conjunction risks could lead impairment companys assets financial position personnel risks earnings could jeopardise continued existence boehringer ingelheim companies exposed boehringer ingelheim demographic change resultant risk affected lack appropriately qualified personnel report expected risk substantial impact companys business activities potential risk therefore developments included longterm planning process many years acquired strategic significance result boehringer ingelheim counters risk means year review intense challenging comprehensive personnel concept regardless time boehringer ingelheim laid ethnic background gender religion offer foundations sustainable development long company employees development opportunities based term growth company several major strategic vocational skills social expertise personal aptitudes decisions increasingly difficult market environment willingness take responsibility accordance increased unpredictability business posed needs company view counter major challenges entire pharmaceutical industry measures described risk regarded concrete continue require significant attention boehringer ingelheim regard competi sectorspecific risks tiveness important therefore boehringer ingelheim exposed business risks specific retain scope growth innovation pharmaceutical industry risks continue successful market future materialised past financial year changes healthcare system usa increasing also continue renew product portfolio significance result impact boehringer financial year product launches forming ingelheim continue classed abstract basis future economic success clinical trials showed new medicines offer addition loss exclusivity products established patients significant therapeutic benefit example market risks associated development new diabetes medicine jardiance first kind registration new products risks increasingly whose active substance regulates blood sugar include changing restrictive requirements relating level also reduces number deaths due cardio pricing reimbursement many sales markets fre vascular incidents patients type diabetes quently prices pharmaceutical products subject increased risk cardiovascular disease jardiance state monitoring regulation also sold part strategic alliance boehringer price pressure cheaper generic drugs caused ingelheim eli lilly longterm collaboration state reimbursement systems boehringer ingelheim joint development marketing diabetes active group management report ingredients continued also comprises increasing cost pressure healthcare system active ingredients ready market singled particular reason fewer next years approvals praxbind fewer companies prepared invest large amounts specific reversal agent anticoagulant pradaxa proper development new medicines result europe usa ofev offers people significant price pressure major markets rare fatal respiratory disease ipf new treatment option prescription medicines conjunction longer improves life expectancy spiolto planning development cycles new products improves already positive therapy results makes business less predictable requires us recog spiriva treatment copd laid foundations nise seize opportunities quickly one hand offsetting expected decrease sales result subjecting costs strategies continual moni loss exclusivity rights medicines toring adjustments end instigated initiatives past years accelerate regard many changes healthcare systems reactions change reduce organisational com increasing price pressure particularly well plexities lower cost base order create established medicines many major markets potential investments thus secure regard increasing challenges market access companys longterm success difficult market new products expect see low growth impetus environment one hand potential resulting pharmaceutical industry coming year measures introduced well boehringer ingelheim asserted difficult promising new product launches expect environment created basis growth see operating result special effects expect see minor increase reve company transactions slightly last years level nues compared previous year adjusted currency effects familyrun company long history strong tradition boehringer ingelheims primary aim main research development costs remained high tain firms independence competitiveness keeping strategy drive growth promote longterm sustainable organic growth still takes new products future primarily products precedence shortterm profit targets confi research development facilities invest dent achieve ambitious targets thanks area care close investigation thera great innovative strength based comprehensive peutic benefit associated prospects success portfolio prospective products global presence comprehensive portfolio prospective products support highly qualified motivated promising study outcomes along newly approved employees current product launches expansions products significant sales potential justifies high emerging markets boost growth areas level investment research development business continue stand vision value plan invest research development innovation research develop innovative new pharmaceutical products similar level year products offer high medical benefits bring review market aim endeavours make new medicines available enable doctors treat patients addition patent expiry attacks patents effectively currently possible major challenges facing researchdriven pharmaceuti cal industry increasing amount investment rd well bigger hurdles increased costs associ ated product approvals context consolidated financial statements boehringer ingelheim consolidated financial statements c n l e f n n c l e e n overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements auditors report overview major consolidated companies boehringer ingelheim overview major consolidated companies c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim microparts gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim sro biopharmaceuticals gmbh prague ingelheim china p boehringer ingelheim veterinary finland boehringer ingelheim research center gmbh co kg international trading shanghai hannover boehringer ingelheim co ltd shanghai finland ky espoo philippines norway boehringer ingelheim boehringer ingelheim phil inc manila norway ks asker poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag consolidated financial statements c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos aires france sas paris taiwan ltd taipeh boehringer ingelheim animal health operations bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceuticals pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni roxane laboratories inc pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd columbus ohio boehringer ingelheim china japan p r seoul boehringer ingelheim investment co ltd shanghai vetmedica inc boehringer ingelheim vetmedica nippon boehringer ingelheim spain p st joseph missouri china investment co ltd shanghai co ltd tokyo boehringer ingelheim boehringer ingelheim animal health ssp co ltd tokyo boehringer ingelheim roxane inc columbus ohio espaa sa barcelona operations china co ltd taizhou boehringer ingelheim boehringer ingelheim vetmedica japan co ltd boehringer ingelheim sa barcelona fremont inc columbia p tokyo europharma sa barcelona fremont california boehringer ingelheim boehringer ingelheim sa seiyaku co ltd yamagata laboratorios fher sa barcelona bogot venezuela boehringer ingelheim japan inc tokyo sweden boehringer ingelheim ca caracas denmark p boehringer ingelheim ab stockholm boehringer ingelheim mexico p r danmark copenhagen boehringer ingelheim switzerland promeco sa de cv boehringer ingelheim ecuador mexico city schweiz gmbh basel boehringer ingelheim vetmedica boehringer ingelheim del ecuador pharmaton sa lugano sa de cv guadalajara cia ltda quito consolidated financial statements consolidated balance sheet boehringer ingelheim consolidated profit loss statement c h boehringer sohn ag co kg ingelheim consolidated balance sheet assets millions eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets deferred charges prepaid expenses deferred taxes total assets liabilities equity millions eur notes shareholders capital group reserves balance sheet currency conversion difference net income equity minority interests group equity negative difference acquisition companies provisions accounts payable liabilities deferred charges deferred taxes total liabilities equity explanation see relevant section notes consolidated financial statements consolidated financial statements c h boehringer sohn ag co kg ingelheim consolidated profit loss statement millions eur notes net sales changes inventories internal work performed capitalised operating income total revenues material costs personnel costs amortisation intangible depreciation tangible assets operating expenses operating income financial income holding income income taxes taxes income taxes thirdparty share net income explanation see relevant section notes consolidated financial statements due legal requirements disclosure shareholders personal taxes arising consolidated business activities tax expenses allowed taxes shown withdrawals accrued group capital items consolidated profit loss statement show value due rounding millions eur disclosed consolidated financial statements cash flow statement boehringer ingelheim statement changes group equity c h boehringer sohn ag co kg ingelheim cash flow statement millions eur income taxes including thirdparty share writedowns writeups fixed assets change provisions pensions cash flow change provisions noncash income expenses gain loss disposals fixed assets change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities interest income interest expenses income tax expenses income income taxes paid cash flow operating activities investments intangible assets investments property plant equipment investments noncurrent financial assets proceeds disposals intangible assets proceeds disposals tangible assets proceeds disposals noncurrent financial assets interest received cash flow investing activities cash receipts grants interest paid cash payment owners cash receipts minority shareholders cash proceeds borrowings loans cash flow financing activities change liquid funds cash relevant transactions changes liquid funds due exchange rate movements remeasurements financial funds financial funds changes liquid funds due drs financial funds changes due drs excl fixedasset securities liquid funds securities within fixed current assets source funds use funds consolidated financial statements c h boehringer sohn ag co kg ingelheim statement changes group equity sharehol accrued thereof cur minority thereof cur millions eur ders capital group capital rency effects equity interests rency effects group equity balance contributions withdrawals net income changes balance contributions withdrawals net income changes balance shareholders capital consists equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consists limited partners capital contribution shareholders personal taxes arising consolidated business activities shown withdrawals accrued group capital items statement changes equity show value due rounding millions eur disclosed consolidated financial statements notes boehringer ingelheim c h boehringer sohn ag co kg ingelheim notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements group management report section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euro accordance section conjunc tion section hgb improve clarity transparency consolidated financial statements individual items con solidated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes information companies included consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable managing shareholder company besides c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg whose general partner controlled c h boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad addi tion c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg companies c h boehringer sohn ag co kg directly indirectly holds majority voting rights included consolidated financial statements full consolidation rules accordance section hgb companies included consolidation report ing year individually collectively insignificant terms net assets financial position group earnings total amount sales equity net income year companies included consolidation account less aggregated group financial statements totals companies also classified associates accordance section hgb due lack consolidated financial statements significance two companies ongoing restrictions control due terms articles association companies consolidated accordance section hgb total number affiliated companies fell one compared previous year one company founded one company liquidated one previously affiliated company reclassified investment following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim vetmedica gmbh ingelheim boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierungs gmbh ingelheim boehringer ingelheim rd beteiligungs gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim following subsidiary companies exempt duty prepare disclose annual financial state ments management reports accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiary companies consolidation first time accordance section hgb companies included consolidation first time date company became subsidiary carrying amount shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remaining balance offsetting capitalised goodwill consolidated financial statements notes boehringer ingelheim currency translation assets liabilities resulting foreign currency transactions translated using middle spot exchange rate balance sheet date realisation principle section conjunction section hgb historical cost convention section conjunction section hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euro accordance section hgb using modified closing rate method using modified closing date rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation difference generally reported within consolidated equity reserves difference equity currency translation annual financial statements countries hyperinflation expected foreign currency effects already recognised within currency translation accordance section hgb financial statement ii level improve true fair view consolidated financial statements exchange rates important currencies group changed follows reporting year basis eur yearend rate average annual rate us dollar japanese yen pound sterling canadian dollar consolidated financial statements accounting policies fixed assets acquired intangible assets tangible fixed assets carried cost less scheduled straightline amortisa tion depreciation determined consideration technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired production costs include materials labour manufacturing costs appropriate portion materials labour overheads depreciation fixed assets extent caused production capitalised intangible assets finite useful lives goodwill firsttime consolidation shareholdings usually amortised period five years useful life ten years applied goodwill boehringer ingelheim korea ltd acquired past experience products sales markets together business conditions boehringer ingelheim korea ltd indicates presents true fair view financial assets essentially included shareholder rights securities loans carried lower cost fair market value impaired current assets prepaid expenses inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured production cost basis individual calculations taking account directly attributable costs materials direct labour costs special direct costs appropriate share production materials overhead costs depreciation goods resale valued lower either purchase cost fair market value identifiable risks inventory assets arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments consolidated financial statements notes boehringer ingelheim inventories valued lossfree ie deductions made expected sales prices reflect costs yet incurred receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets include securities recognised lower cost quotedmarket prices reporting date cash cash equivalents consisting cash balances banks cheques recognised lower cost fair market value deferred charges prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred charges recorded accordance section hgb include proceeds represent income respect defined period time balance sheet date negative difference acquisition companies negative difference acquisition companies recognised following acquisitions march august value net assets acquired exceeded purchase prices paid value negative difference acquisition companies amounted eur million january increased acquisition company acquired august eur million negative difference acquisition companies amortised estimated period ten years release negative difference acquisition companies eur million financial year eur million shown oper ating income release consistent depreciation amortisation excess assets date acquisition consolidated financial statements group reserves group reserves include retained earnings consolidated subsidiaries prior years consoli dation entries affect earnings related previous years provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judgement ie including future cost price increases provisions remaining term one year discounted using matchedterm average market interest rate last seven years accord ance rckstellungsabzinsungsverordnung german regulation discounting provisions liabilities liabilities recognised settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred charges commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reversed measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using company specific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without setoff consolidated financial statements notes boehringer ingelheim notes consolidated balance sheet intangible assets acquired concessions advance millions eur similar rights goodwill payments total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements tangible assets advance technical facilities payments land facilities operating construction millions eur buildings machines equipment progress total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes boehringer ingelheim financial assets investments loans investments affiliated affiliated related investment millions eur companies companies companies securities loans total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortisation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders consolidated financial statements inventories millions eur raw materials supplies unfinished products finished products goods resale advance payments suppliers accounts receivable assets residual residual term term millions eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders eur million previous year eur million receivables affiliated companies previous year almost exclusively consist receivables loans receivables related companies essentially consist trade accounts receivable provisions millions eur pension provisions tax provisions provisions consolidated financial statements notes boehringer ingelheim provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg germany mortality tables g published prof dr klaus heubeck pension obligations significant countries calculated basis following actu arial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions november interest rates used discount significant foreign pension obligations usa japan determined comparable param eters line german regulation discounting provisions november plan assets intended solely cover pension similar obligations unavailable cred itors plan assets defined section hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date eur million corresponding amount required settle offset pension obligations similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accordance section hgb total eur million earnings plan assets eur million interest expense relating pension similar obligations included financial result consolidated financial statements liabilities residual term residual term less less millions eur year years years year bank loans accounts payable trade accounts payable advance payments accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million presented within liabilities accounts payable affiliated companies include loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million consolidated financial statements notes boehringer ingelheim notes consolidated profit loss statement structure consolidated profit loss statement based total cost format net sales business business segment millions eur prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales geographic region millions eur europe germany americas usa asia australia africa japan operating income operating income includes income currency translation eur million previous year eur million material costs millions eur costs raw material supplies goods resale expenditure services consolidated financial statements personnel costs millions eur salaries wages social benefits retirement benefits retirement benefits interest effects measurement provision pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices amortisation intangible assets depreciation tangible assets amortisation intangible assets depreciation tangible fixed assets include extraordinary writedowns eur million previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million addition operating expenses also include thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties consolidated financial statements notes boehringer ingelheim financial result millions eur interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial assets shortterm investments income investment securities longterm loans interest income similar proceeds holding income millions eur writeoffs financial assets income related companies disposal related companies taxes millions eur income taxes deferred taxes current income taxes essentially include corporation trade tax expenses companies included consolidation result conclusion profit transfer agreements significant german corporations included trade corporation tax group parent company c h boehringer sohn ag co kg since january income taxes shareholders c h boehringer sohn ag co kg incurred operating income reported consolidated profit loss statement tax expenses represent trade income tax affected companies fully consolidated german partnerships consolidated financial statements total deferred tax assets amounted eur million balance sheet date deferred tax assets primarily relate differences carrying amounts recognised provisions fixed assets inventories deferred tax liabilities eur million recognised primarily relate differences carrying amounts tangible assets inventories provisions net income net income positively influenced priorperiod operating income essentially reversal provisions eur million previous year eur million negatively influenced priorperiod operating expenses eur million previous year eur million notes cash flow statement cash flow statement shows changes cash cash equivalents cash longterm securities investments classified current assets sold time boehringer ingelheim group resulting cash outflows reporting year accordance german accounting standard cash flow statement gas cash flow statement broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial funds comprise financial assets remaining maturity excess months date acquisition financial assets converted cash shortterm financial funds comprise following items millions eur cash cash equivalents securities financial assets financial year interest eur million received eur million previous year eur million interest paid tax payments amounted eur million previous year eur million consolidated financial statements notes boehringer ingelheim disclosures contingent liabilities millions eur liabilities guarantees bills cheque guarantees warranties granting security thirdparty liabilities risk utilisation individual contingent liabilities estimated follows risk utilisation guarantees liabilities banks affiliated companies rated low account solid net assets financial position results operations subsidiaries question financial commitments offbalance sheet transactions millions eur rental leasing obligations purchase commitment obligations rental lease agreements eur million previous year eur million eur million previous year eur million relate longterm rental agreements sub sidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilise properties fully indications time financial commitments include future expenses followup investments investments already initiated future major repairs balance sheet date purchase commitments include future cash flow effects investments totalling eur million previous year eur million derivative financial instruments valuation units owing extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks consolidated financial statements use derivative financial instruments organisational processes set internal guide lines strict separation trading processing documentation control risk positions regularly tracked analysed measured special groupwide financial report positions entered periodically reevaluated monitored fair market values derivative financial instruments calculated using standard market measurement methods currency interest forwards using net present value method currency interest options using recognised option pricing models basis market data available balance sheet date currency interest options recognised fair market value exceeding option premium paid received derecognised maturity provisions eur million recognised currency forwards included hedge accounting negative fair market value within currency balance sheet date line imparity principle positive fair market values within currency recognised balance sheet date derivative financial instruments included hedge accounting valuation groups follows nominal value market value millions eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecasted transactions accordance section hgb met foreign currency forward exchange contracts recognised balance sheet line net hedge presentation method following accounting policies apply recognition hedges accordance section hgb economic hedges accounted financial statements use valuation groups valuation groups recognised foreign currency based net amount highly probable forecasted trans actions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable consolidated financial statements notes boehringer ingelheim opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges december hedges highly probable forecast net cash flows recognised follows january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy gbp gbp gbp consolidated financial statements january february net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy furthermore december hedges foreign currency receivables recognized follows receivables millions eur forward exchange contracts millions eur nominal value nominal value market value rub rub rub pln pln pln amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecast transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur million without hedging balance sheet date one floatingrate loan amounting eur million interest rate swaps matching amounts matching maturities concluded hedge associated interest rate risk exclusively purpose converting floatingrate loan portions fixed rate use made hedge accounting micro hedges opposing changes value hedged item hedging instrument fully offset due matching critical terms interest rate swaps including accrued interest negative fair market value eur million balance sheet date carrying amount equal deferred accrued interest eur million reported liabilities banks net hedge presentation method used research development expenses millions eur research development expenses noncapitalised research development expenses include amongst items costs associated phase iv clinical studies total auditor fees total fees charged group auditor financial year eur million eur million relates audits financial statements eur million assurance services eur million services consolidated financial statements notes boehringer ingelheim auditors report audited consolidated financial state conducted audit consolidated financial ments prepared ch boehringer sohn ag statements accordance article hgb co kg ingelheim comprising balance handelsgesetzbuch german commercial code sheet income statement statement changes german generally accepted standards equity cash flow statement notes audit financial statements promulgated consolidated financial statements together institut der wirtschaftsprfer institute public group management report busi auditors germany idw standards ness year january december require plan perform audit preparation consolidated financial misstatements materially affecting pres statements group management report entation net assets financial position accordance german commercial law results operations consolidated financial responsibility managing directors statements accordance german principles managing corporate general partner responsi proper accounting group manage bility express opinion consolidated ment report detected reasonable assurance financial statements group management knowledge business activities eco report based audit nomic legal environment group expectations possible misstatements taken account determination audit proce dures effectiveness accountingrelated internal control system evidence support ing disclosures consolidated financial statements group management report examined primarily test basis within frame work audit audit includes assessing annual financial statements companies included consolidation determination companies included consolidation accounting consolidation principles used significant estimates made managing directors managing corporate general partner well evaluating overall presentation con solidated financial statements group man agement report believe audit provides reasonable basis opinion consolidated financial statements exception following qualification audit led reservations contrary article nos b hgb total remuneration granted members former members board managing directors members supervisory body well pension provisions recognized recognized former members board managing directors disclosed notes consolidated financial statements opinion based findings audit qualification mentioned consolidated financial statements comply legal requirements consolidated financial statements give true fair view net assets financial position results operations group accordance german principles proper accounting group management report consistent consolidated financial statements comply legal requirements whole provides suitable view groups position suitably presents oppor tunities risks future development frankfurt main february pricewaterhousecoopers aktiengesellschaft wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german certified german certified public accountant public accountant product portfolio boehringer ingelheim pprroodduucctt ppoorrttffoolliioo p r u c po r f l e l e c n branded prescription medicines consumer health care animal health product portfolio branded prescription medicines boehringer ingelheim branded prescription medicines respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder among prevalent chronic diseases frequent airways inflammation accompanied air cause morbidity premature deaths worldwide way hyperresponsiveness leads narrowing airways recurrent episodes wheezing breath idiopathic pulmonary fibrosis ipf rare disease lessness coughing symptoms occur particularly severely debilitating ultimately lethal night early hours morning known asthma triggered genetic envi copd ronmental factors eg allergens viral infections copd chronic disease lungs causes cough unlike copd asthma occur early childhood ing excessive mucus production inflammation also present adolescents adults asthma often ultimately destroys lung tissue alveoli thus underestimated easy manage condition however gas exchange affected lead limita almost one two patients asthma still experience tion airflow causing shortness breath res symptoms receiving maintenance therapy putting piratory symptoms airflow limitation partially increased risk potentially lifethreatening reversible usually worsens time leading disa asthma exacerbations bility ultimately death symptoms excess cough breathlessness main reasons copd stressful patients lung emphysema chronic bronchitis main manifestations copd copd caused continuous damage lungs result ing inhaling pollutants primarily cigarette smoke however factors also need considered includ ing indoor outdoor air pollution course copd disease occurs second half humans life characterised accelerated loss lung function compared normal ageing occasional sud den worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms even inactivity product portfolio indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd spiriva handihaler copd including chronic bronchitis spiriva respimat emphysema maintenance treat ment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patients asthma currently treated maintenance combination inhaled corticosteroids spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patients chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patients pulmonary disease copd hyrochloride chronic obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination short acting anticho associated obstructive salbutamol sulphate linergic betaadrenergic airway diseases management reversible bronchos pasms associated obstructive air way diseases patients requiring one bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonists cases acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment broncho disorders bronchodual hydrobromide spasm patients asthma duovent chronic obstructive pulmonary disease copd product portfolio branded prescription medicines boehringer ingelheim respiratory diseases continued idiopathic pulmonary fibrosis ipf result individuals ipf experience shortness ipf progressive lung disease associated markedly breath even resting often difficulty reduced life span affecting many people participating everyday physical activities per worldwide ipf characterised progressive scarring lung tissue loss lung function time acute ipf exacerbations defined rapid deteriora development scarred tissue called fibrosis time tions symptoms lung function within days tissue thickens stiffens scarring lungs weeks events occur point course lose ability take transfer oxygen disease even first presentation patients bloods tream vital organs get enough oxygen ipf risk acute ipf exacerbations cardiovascular diseases cardiovascular diseases leading causes death transient ischaemic attack tia similar stroke many countries still increasing prevalence last minutes hours usually result permanent neurological damage tia may stroke precede stroke emergency medical care subsequent stroke rapidly developing loss brain functions preventive treatment necessary due reduced blood flow affected brain tissue due ischaemia lack blood supply caused acute myocardial infarction thrombosis embolism due bleeding acute myocardial infarction heart attack result affected area brain unable function acute event occurs thrombus clot suddenly damage quickly becomes permanent untreated prevents blood flow area heart muscle unless stroke acute event requiring emergency diagnosis blood flow restored quickly affected section intervention worldwide stroke one leading heart muscle becomes permanently damaged heart attack causes death longterm disability symptoms leading cause death developed countries product portfolio indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib esylate treatment patients idiopathic ipf pulmonary fibrosis ipf indications brand names active ingredients h ypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocar mortality prevention micardis plus dial infarction heart attack stroke death cardiovascular cv causes micardishct patients years age older high comicardis risk developing major cv events unable take ace inhibitors usa reduction cardiovascular morbidity patients manifest atherothrombotic cardiovascular dis ease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus documented target organ damage eu hypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multi ple antihypertensive agents achieve micardis duo blood pressure goals usa addon therapy adult patients adequately controlled blood pres sure amlodipine replacement therapy adult patients receiving tel misartan amlodipine separate tablets eu product portfolio branded prescription medicines boehringer ingelheim cardiovascular diseases continued hypertension cardiovascular diseases prevention venous thromboembolism hypertension also referred high blood pressure patients undergoing orthopaedic surgery consider chronic disease blood pressure chronically able risk developing deep vein thrombosis legs elevated hypertension also one major risk factors potentially fatal pulmonary embolism also strokes heart attacks heart failure chronic renal known venous thromboembolism vte thrombo failure embolic events may recur chronic venous insuffi ciency andor pulmonary hypertension may develop one billion people worldwide affected hyper longer term prevent vte events conse tension prevalence hypertension increases steadily quences patients receive kind thrombo age world population ageing preventive prophylaxis strategies terms lifestyle changes far failing swiftly increasing incidence obesity prevalence treatment venous thromboembolism hypertension set increase even vte umbrella term encompasses deep vein thrombosis dvt pulmonary embolism pe dvt hypertension major risk factor cardiovascular process occurs thrombus blood clot forms morbidity mortality organs risk primarily deep vein commonly calf leg par heart main blood vessels brain kid tially completely blocks flow blood one neys primary goal antihypertensive treatment major contributing factors dvt pathogenesis venous prevent cardiovascular events heart attacks stasis thrombus grows portion may break away strokes finally reduce cardiovascular mortality main clot travel circulatory system lungs lodging blood clot arteries cardiovascular disease cvd responsible nearly one lung called pe vte serious disorder poten three deaths worldwide thus number one tially fatal consequences patients already suffer medically related cause death proper control treat vte require anticoagulant treatment secondary able risk factors disease therefore vital prevention recurrent thromboembolic event prevention cardiovascular events reversing anticoagulation atrial fibrillation anticoagulants offer important benefits patients risk patients atrial fibrillation af higher risk thromboembolic events however even though rare developing blood clots cause disabling stroke situations rapid reversal anticoagu clots travel brain af common lation could medically necessary type arrhythmia associated hypercoagula ble state predisposes stroke systemic embolism prevented effective chronic anticoagulation product portfolio indications brand names active ingredients secondary prevention aggrenox dipyridamole prevention stroke following stroke transient ischaemic asasantin acetylsalicylic acid initial first stroke transient ischaemic attacks tia asasantin retard attacks tia h ypertension catapresan clonidine treatment hypertension catapres hydrochloride clonidine catapressan cataprestts acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occluded cath catheter clearance due eters thrombotic occlusion acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension motens lacidipine treatment hypertension stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic events orthopaedic surgery primary prevention venous thrombo treatment secondary embolic events vte adults prevention venous throm elective total hip knee replacement boembolic events surgery treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adults specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated adult patients treated pradaxa dabigatran etexilate rapid reversal anti coaculant effects required emer gency surgeryurgent procedures lifethreatening uncontrolled bleeding product portfolio branded prescription medicines boehringer ingelheim metabolic diseases diabetes type diabetes chronic progressive condition average decreased twelve years approxi cause longterm complications well controlled mately per cent deaths people type diabetes caused cardiovascular disease every year million deaths worldwide linked directly longterm effects diabetes type diabetes addition cardiovascular disease serious complica common form accounts cases tions diabetes include nephropathy leading renal developed world affects million people failure potential risk dialysis retinopathy worldwide imposing enormous burden health potential loss vision increased incidence stroke care systems globally without effective prevention cardiovascular diseases peripheral neuropathy management estimated number cases risk foot ulcers foot leg amputations reach million type diabetes one autonomic neuropathy causing gastrointestinal genitouri major risk factors cardiovascular disease life expectancy nary cardiovascular symptoms sexual dysfunction people type diabetes high cardiovascular risk product portfolio indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment type diabetes mellitus tradjenta improve glycaemic control adults trazenta used monotherapy metformin tolerated contraindicated trayenta combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment type diabetes mellitus trayenta duo improve glycaemic control adults trajenta duo treatment metformin lead sufficient control trajentamet patients treated trajenta linagliptin metformin type diabetes mellitus jardiance empagliflozin treatment type diabetes mellitus jardianz improve glycaemic control adults used monotherapy diet exercise alone provide adequate glycaemic control metformin considered inappropriate due intoler ance combination therapy type diabetes mellitus synjardy empagliflozin treatment type diabetes mellitus metformin improve glycaemic control adults hydrochloride treatment metformin lead sufficient control patients treated jardiance empagliflozin metformin type diabetes mellitus glyxambi empagliflozin linagliptin treatment type diabetes mellitus improve glycaemic control adults treatment empagliflozin linagliptin appropriate us product portfolio branded prescription medicines boehringer ingelheim oncology cancer threat global health estimated symptoms unspecific may take many years million new cases cancer diagnosed world appear late diagnosis advanced stage disease wide million people died cancer results often dismal prognosis lung common diagnosed cancer types lung cancer cancer patients surviving five years following breast cancer colorectal cancer diagnosis lung cancer lung cancer one disease dif lung cancer refers malignant abnormal cell growth ferent subtypes small cell lung cancer sclc inside lung tissue forming cluster tumour nonsmall cell lung cancer nsclc differ common cancer estimated million ent molecular genetic aberrations mutations present new cases per year worldwide smoking pri tumour identified focusing molecu mary cause disease contributing lar changes specific respective subtype cases recently however incidence lung cancer lung cancer targeted therapies become effec among non smokers women increased lung tive treatments showing survival benefit cancer poor prognosis million deaths per time less harmful normal cells year representing cancer deaths lung cancer thereby reducing side effects diseases central nervous system mental neurological diseases depression dementia depression sleep disorders parkinsons disease significantly impact patients primary symptoms result lack neuro families also substantial burden society transmitter dopamine distinct areas human brain parkinsons disease restless legs syndrome rls parkinsons disease pd degenerative disorder restless legs syndrome rls common neurological central nervous system patients usually notice motor disorder characterised uncontrollable urge move symptoms like hand tremor shaking first sign legs primarily occurring evening night disease progresses eventually include shak hours usually accompanied unpleasant ing arms legs head motor symptoms times painful sensations legs well disturbed may develop time include stiffness often results sleep resulting daytime tiredness sleepiness loss facial expression gradual slowing loss sensations felt deep within legs described motion freezing patients also creeping crawling aching suffer nonmotor symptoms associated pd product portfolio indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib treatment patients nsclc gilotrif metastatic nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders lindormin initiating maintaining sleep insomnia requiring pharmacological intervention product portfolio branded prescription medicines boehringer ingelheim infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immu nodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals susceptible opportunistic infections tumours babies infected mothers risk getting virus pregnancy childbirth breastfeeding product portfolio indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv viramune xr infection several countries prevention mothertochild trans mission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treatment hivinfected patients coadministered mg ritona vir treatmentexperienced infected hiv strains resistant one protease inhibitor product portfolio consumer health care boehringer ingelheim consumer health care cough cold mucosolvan ambroxol bisolvon bromhexine dextromethorphan symptomatic treatment indicated secretolytic therapy broncho irritable nonproductive cough marketed vari pulmonary diseases associated abnormal mucus ety tradenames specific countries central secretion impaired mucus transport cough suppressant effect aiming normalize cough threshold cough common symptom clinical impor tance frequent reason consulting doctor mucoviral bisolviral antiviral nasal sprays visiting pharmacy clinical symptoms cough launched sprays contain iotacarra expectoration led development drugs geenan extracted natural red seaweed affect respiratory mucus ie mucoactive agents applied nasally iotacarrageenan acts like protective layer physically inhibits infection nasal epithe mucosolvan promotes mucus clearance facilitates lial cells cold viruses since viruses dock expectoration eases productive cough allowing specific receptors cell surface clinical trials patients breathe freely deeply available many use mucoviralbisolviral shown different product forms formulations typically reduce viral load patients nasal secretion based active ingredient ambroxol relieve symptoms cold ambroxol mucoactive drug several properties boxagrippal launched germany following including secretolytic secretomotoric actions successful switch prescription overthecounter restore physiological clearance mechanisms otc medicine status cold remedy combines respiratory tract play important role bodys antiinflammatory pain reliever nsaid ibuprofen natural defence mechanisms ambroxol stimulates syn oral decongestant pseudoephedrine hydrochloride thesis release surfactant type ii pneumocytes treat troublesome symptoms cold blocked nose sinuses combination headache fever bisolvon bromhexine market since coldrelated pain bromhexine contained various formulations bisolvon shown increase proportion active ingredient tramazoline treatment serious bronchial secretion making easily blocked noses available number countries expectorated bromhexine also enhances mucus trans range brand names including rhinospray port reducing mucus viscosity activating muconasal lasolvan rhino ciliated epithelium product portfolio indications brand names active ingredients acute chronic broncho mucosolvan ambroxol secretolytic therapy acute chronic pulmonary diseases mucosan bronchopulmonary diseases associated surbronc abnormal mucus secretion impaired mucus transport lasolvan mucopect acute chronic broncho bisolvon bromhexine secretolytic therapy acute chronic pulmonary diseases bronchopulmonary diseases associated abnormal mucus secretion impaired mucus transport irritable cough silomat dmp dextromethorphan symptomatic treatment irritable bisoltussin nonproductive cough bisolvon dry bisolsek bisolvon antitusivo mugotussol mucotussin surbronc toux sche common cold mucoviral iotacarrageenan antiviral treatment common cold bisolviral also used sustained moisturi surbroncviral sation nasal mucosa common cold boxagrippal ibuprofen symptomatic treatment nasal conges bisolfren pseudoephedrine tion combination headache fever nasal congestion rhinospray tramazoline relief swelling nasal rhinospray plus mucosa ie nasal congestion associated muconasal common cold hay fever facilitate drainage secretion lasolvan rhino sinusitis otitis media lasorin spraytish rinogutt product portfolio consumer health care boehringer ingelheim sore throat sore throat product range offers solutions local anaesthetic effect described first sore throat pain hoarseness late efficacy safety mucoangin shown several recent clinical trials mucoangin main brands tratment sore throat available lozenges variety flavours since mucoangin lysopaine also spray format mucoangin ambroxol indicated pain relief lysopaine cetylpyridinium lysozyme combines well acute sore throat pain sore throat hallmark known antiseptic enzyme plays key role acute pharyngitis usually caused viral infection bodys natural immune system antibacterial formula infection rule selflimiting patient indicated sore throat low intensity without fever mally recovers days bothersome patient continuous pain throat voxlysopainelizivoz lozenge double layer maximised swallowing main goal treat natural iceland moss alum offers double ment thus reduce pain effect soothes mucous membrane back throat calms hoarseness also acts like barrier addition secretolytic activity ambroxol potent protecting throat attacks outside inhibitor neuronal sodium channels shown product portfolio indications brand names active ingredients sore throat mucoangin ambroxol pain relief acute sore throat lysopadol lysopain dol isodinemint lizipadol zerinol gola sore throat lysopaine cetylpyridinium lysozyme local adjuvant treatment sore throat low intensity without fever adults children years old hoarseness voxlysopaine iceland moss alum helps reduce hoarseness improve lizivoz strength voice lysopain voice zerinolvox product portfolio consumer health care boehringer ingelheim pain boehringer ingelheims overthecounter otc pain port three components suppress pain synergistically via folio consists number leading brands different interaction several painr elated molecular mecha countries around world brand eve leading nisms result thomapyrin classic offers faster analgaesic japanese otc market eve offers products superior efficacy compared single components based innovative ibuprofen formulations also proven current clinical studies specifically tailored needs female consumer leading products eve eve quick eve ex reason triple combination recommended latter innovative fast releasing galenical form many national international medical societies first developed boehringer ingelheim scientists japan choice acute treatment tensiontype headaches migraines thomapyrin positioned expert treat brazil anador general pain brand moderate ment headaches several line extensions vailable severe pain leading position market thomapyrin classic headache thomapyrin inten metamizole principle active ingredient anador siv stronger headache brand thomapyrin comprises products another brand finalgon nonivamid nicoboxil treatment acute pain mild moderate intensity topical cream joint muscle pains primarily available germanspeaking countries thomapyrin classic core product thomapyrin brand composed triple combi nation acetylsalicylic acid paracetamol caffeine product portfolio indications brand names active ingredients pain eve ibuprofen adults older years reduc eve quick allylisopropylacetylurea dehydrated tion fever temporary relief mild eve ex caffeine magnesium oxide moderate aches pains associated headache menstrual pain body pains available japan eve quick pain anador metamizole moderate severe acute pain lisalgil sodiummetamizole magnesium including colicky pain tumor pain nolotil high fever responding general therapeutic measures prodolina available brazil pain thomapyrin classic acetylsalicylic acid adults adolescents older thomapyrin paracetamol caffeine years acute treatment mild intensiv moderate headache migraine attacks without aura treat ment tensiontype headache available germany pain lonarid paracetamol codeine phosphate moderate severe pain adults lonarid n paracetamol codeine phosphate adolescents aged years older prontalgine caffeine adults adolescents years age older symptomatic treat ment moderate severe pain responding peripheral analgesics available france pain finalgon nonivamid nicoboxil stimulate blood flow skin treating joint muscle complaints product portfolio consumer health care boehringer ingelheim gastrointestinal diseases gastrointestinal portfolio offer several brands buscopan preferred choice reliable relief dulcolax surulac laxoberal guttalax pain discomfort due abdominal cramps buscopan vaprino well heartburn brands unique proven formula gently relaxes cramped mus zantac gastol cles digestive tract acts pain occurs thus relieving spasms cause abdominal constipation common problem dulcolax pain active ingredient buscopan hyoscine leading overthecounter otc laxative remedy con butylbromide derived natural substance stipation relief worldwide extracted duboisia plant dulcolax tablets special enteric comfort coating buscopan offers full line products mono vari ensures active ingredient dulcolax ant also different combinations analgesics par tablets bisacodyl taken needs act acetamol ibuprofen metamizoldipyrone well colon stimulates natural movement bowels different formats tablets drops suppositories syrup provide gentle predictable relief hours one solutions intravenous injection two tablets taken going bed provide relief next morning umbrella brand buscopan also offers buscofem menstrual pain relief products within dulcolax range include dulcoease dulcoenema dulcosoft dulcogas extended gastrointestinal portfolio vaprino selfmedication product diarrhoea surulac constipation brand japan consum active ingredient racecadotril effective various forms ers offered surulac laxative tablet laxoberal acute diarrhoea reducing excessive secretion guttalax brands offering consumers consti gut without changing gastrointestinal transit time pation relief flexible dosage format namely drops motility thanks new way action vaprino ena bles fast relief diarrhoea without blocking bowels abdominal cramping pain discomfort common ailments approximately one four persons worldwide zantac brand ranitidine owned usa suffers regular basis boehringer ingelheim represents one leading heartburn brands market product portfolio indications brand names active ingredients constipation dulcolax bisacodyl laxative use patients suffering surulac bisacodyl sennoside constipation preparation diagnostic procedures pre postoperative treatment condi tions require defecation facili tated constipation laxoberal sodium picosulphate laxative use cases constipation laxoberon conditions require defeca guttalax tion facilitated dulcolax np constipation dulcosoft macrogol laxative used symptomatic treat ment constipation allows soften hard feces facilitate disposal gas bloating dulcogas simethicone fastacting granules relieve gas bloating prevent flatulence abdominal pain buscopan hyoscine butylbromide treatment relief abdominal buscapina hyoscine butylbromide paracetamol cramping pain discomfort buscopan plus buscapina plus acute diarrhoea vaprino racecadotril treatment symptoms acute diar rhoea adults heartburn zantac ranitidine fast lasting relief heartburn available usa product portfolio consumer health care boehringer ingelheim vitamins supplements pharmaton multivitamin brand developed sup pharmaton contains selected blend vitamins port physical mental well full range prod minerals trace elements plus omega main indi ucts developed meet needs different tar cations help maintain cardiovascular health get audiences adult adult children help covering daily needs vitamins minerals omega fatty acids acting complementary daily pharmaton range products adults containing nutrition selected blend vitamins minerals trace elements plus standardised ginseng extract g main pharmaton kiddi range products designed target indications exhaustion tiredness decreasing children contains essential amino acid lysine plus concentration mental alertness well cases selected vitamins minerals important deficient nutrition loss appetite debility due illness period growth support healthy physical convalescence numerous clinical studies shown mental development also recommended regular intake pharmaton positive effect preventive treatment vitamin deficiencies mental physical performance wellbeing product portfolio indications brand names active ingredients tiredness decreasing concen pharmaton ginseng extract improve general wellbeing tration cases deficient pharmaton vitality vitamins minerals support physical mental energy nutrition loss appetite pharmaton geriavit trace elements debility due illness geriatric pharmaton convalescence gericomplex pharmaton complex pharmaton fizzi pharmaton active life help maintain cardiovas pharmaton vitamins minerals improve general wellbeing cular health help cover pharmaton plus omega fatty acids support physical mental energy ing daily needs vita mins minerals omega fatty acids acting comple mentary daily nutrition increased demand vita pharmaton kiddi vitamins covers increased demand vita mins childhood minerals mins minerals amino acids espe amino acids cially period growth pre ventive treatment cases vitamin deficiencies eg cases restricted inadequate diets loss appetite sub sequent illness infections surgery convalescence prophylaxis iron folic pharmaton matruelle vitamins minerals women pregnancy acid deficiency preg trace elements preventing deficiency symptoms nancy omega fatty acids covering increased needs vita docosahexaenoic mins minerals trace elements dha acid dha provide protection embryonal neural tube diseases foetus prophylaxis iron folic acid anae mia pregnancy breastfeeding product portfolio consumer health care boehringer ingelheim leg vein health brand name antistax boehringer ngelheim symptoms antistax helps keep fluid flows markets broad range products developed pre small venous vessels venules surrounding vention treatment symptoms attributable chronic tissue normal levels even standing sitting venous insufficiency common symptoms long time venous insufficiency observable consumers varicose veins oedema lower leg heavy tired legs sensation red vine leaf extract active ingredient antistax tension tingling cramps pain antistax tablets products antiinflammatory effect works scientifically proven help maintain healthy leg vein endothelium inside venules sealing circulation inside thereby reducing swelling sensation pain heaviness heavy aching tired legs often occur long periods standing sitting increase end day products available antistax range include ntistax summer outdoor temperatures rise tablets antistax vein creme antistax cooling antistax tablets offer effective treatment described gel legs urological diseases benign prostate hyperplasia bph refers enlargement prostate middleaged elderly men lead lower urinary tract symptoms luts fre quent nighttime urination urge urinate every hours weak flow feeling unfinished urinating product portfolio indications brand names active ingredients chronic venous insufficiency antistax red vine leaf extract prevention treatment symptoms chronic venous insufficiency varicose veins leg oedema painful swollen legs tingling legs tired heavy legs heavy tired legs antistax red vine leaf extract relieves revitalizes tired heavy vein cream legs heavy tired legs antistax red vine leaf extract menthol cools refreshes heavy tired legs fresh leg gel peppermint oil hydrates skin indications brand names active ingredients benign prostate hyperplasia flomax relief mr tamsulosin treatment lower urinary tract symp bph toms luts common condition called benign prostate hyperplasia bph available uk overthecounter otc medication product portfolio animal health boehringer ingelheim foodproducing animals swine infectious respiratory diseases ingelvac mycoflex licensed active immunisa ingelvac circoflex first singledose piglet vaccine tion pigs enzootic pneumonia ep single control porcine circovirus disease pcvd dose regimen advanced adjuvant system vaccine provides significant reduction mortality provides longlasting effective protection proven acute phase pcvd well improved growth rates even highchallenge situations chronic phase disease ingelvac circoflex protects minimal systemic adverse reactions injec infectious enteric diseases tion site swellings used pregnancy enterisol ileitis first vaccine lactation ingelvac prrs products licensed ileitis caused lawsonia intracellularis licensed active immunisation respiratory reproduc improve weight gain reduce growth variability tive form porcine reproductive respiratory syn associated disease enterisol ileitis helps drome prrs reduce total antimicrobial use pork production foodproducing animals poultry volvac umbrella brand boehringer ingelheim various viral bacterial diseases like avian animal health poultry vaccine range consists influenza infectious bronchitis newcastle disease infec wide range live inactivated vaccines broilers tious bursal disease egg drop syndrome avian coryza layers vaccines provide protection birds product portfolio indicat ions brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs iseases porcine circovirus age two weeks porcine type pcv circovirus type reduce mortality clini cal signs including weight loss lesions lymphoid tissues asso ciated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine prrs virus depending product active iseases ingelvac prrsflex eu type prrs mlv immunisation pigs various ages reprocyc type prrsflex eu porcine reproductive reprocyc respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs iseases mycoplasma age three weeks reduce lung hyopneumoniae lesions following infections myco plasma hyopneumoniae infectious enteric diseases enterisol ileitis attenuated live vaccine lawsonia active immunisation pigs intracellularis age three weeks intestinal lesions caused lawsonia intracellularis infection reduce growth variabil ity loss weight gain associated disease indicat ions brand names active ingredients various viral bacterial volvac polyvalent attenuated live vaccination healthy chickens diseases poultry inactivated vaccine diseases caused included containing antigens antigens prevention vaccination avian common diseases broiler chickens influenza newcastle diseases responsible losses egg disease avian coryza egg production layers drop syndrome infectious bronchitis infectious bursal disease bacterium anatis product portfolio animal health boehringer ingelheim foodproducing animals cattle mastitis mastitis inflammation udder dairy cattle mainly caused bacterial infection prevention treatment mastitis animals key producing healthy milk minimising symptoms associated clinical situation mamyzin effective injectable antimicrobial treatment acute masti tis ubrolexin today two products treatment acute bacterial mastitis whereas ubrostar tomorrow used prevent mastitis dry ingoff dairy cattle end lactation period product portfolio indicat ions brand names active ingredients astitis mamyzin penethamate hydroiodide bovine mastitis caused penicillin sensitive organisms astitis ubrostar penethamate hydroiodide framyce treatment subclinical mastitis benestermycin tin sulphate benethamine penicillin drying prevention new mamyzin secado bacterial infections udder dry period dairy cows caused bacteria susceptible penicillin framycetin astitis ubrolexin cefalexin kanamycin combination treatment clinical mastitis lactating dairy cows bacteria susceptible combination cefalexin kana mycin astitis today cephapirin sodium treatment clinical mastitis lactating cefalak dairy cows uscanada astitis tomorrow cephapirin benzathine treatment subclinical mastitis cefadri drying prevention new bacterial infections udder dry period dairy cows uscan ada intramammary infusion dry cow us product portfolio animal health boehringer ingelheim foodproducing animals cattle continued pain inflammatory disorders infectious diseases metacam nonsteroidal antiinflammatory drug pyramid family vaccines providing broad nsaid addresses need maintained profita coverage respiratory reproductive diseases bility concern animal welfare animal pro range consists several antigen combinations duction due longacting nature outstanding efficacy controlling inflammatory symptoms metacam bovine viral diarrhoea virus bvdv one major helps minimise losses inflammation maintain economically relevant cattle pathogens worldwide profitability time metacam e ffectively distribution disease caused bvdv results marked controls pain supports restoration wellbeing production losses dairy beef herds bovela farm animals use metacam c onvenient vaccine designed reduce clinical signs inflicts minimal stress animals due lowvolume typical bvd prevent birth socalled per oneshot dosage sistently infected animals caused transplacental infec tion bvdv vaccination bovela expected metacam licensed adjunctive therapy treat provide protection within herd disease ment mastitis lactating cows countries circulation virus also indicated use calves affected diarrhoea cattle suffering respiratory disease product portfolio indicat ions brand names active ingredients pain inflammatory metacam meloxicam cattle metacam used together isorders appropriate antibiotic therapy reduce clinical signs disease acute respiratory infection used diarrhoea combination oral rehydration therapy reduce clinical signs disease calves one week age young nonlactat ing cattle also used relief postoperative pain following dehorning calves supportive therapy treatment acute masti tis combination antibiotics cattle infectious diseases pyramid several multivalent vaccine combi vaccination healthy dairy beef respiratory reproductive presponse nations including modified live cattle aid prevention diseases diseases cattle viruses bovine viral diarrhoea bvd caused included antigens us types infectious bovine canada rhinotracheitis ibr parainflu enza pi bovine respiratory syncytial virus brsv bacteria pasteurella multocida mannheimia haemolytica l canicola l grippoty phosa l hardjo l icterohaemmor rhagiae l pomona bovine viral diarrhoea bvd bovela modified live bvdv strain bovela used protect cattle modified live bvdv strain bvd viral infection bovine viral diarrhoea virus product portfolio animal health boehringer ingelheim companion animals horse main horse products focus therapeutic areas vetera vaccines formulated utilising ultrafil respiratory disease lameness colic hormonal purification technology removing extraneous pro disorders teins allowing horses immune system focus relevant antigens prascend indicated treatment pituitary pars intermedia dysfunction ppid also known respiratory segment two products available global equine cushings disease prascend substitutes level ventipulmin equisolon products lack dopamine pituitary pars intermedia clinical licensed treatment respiratory disease including airway signs hypertrichiosis laminitis change body con obstruction horses wheeze cough difficulty formation lack performance treatment breathing due bronchospasm andor mucus accumulation prascend lifelong ventipulmin equisolon used alone adjunctive therapy chronic obstructive pulmonary disease vetera vaccines first vaccine portfolio copd acute subacute chronic respiratory allergic include ultiple convenient combinations disease pro conditions tection horses young four months age vaccines protect many nine infectious organisms including influenza herpes west nile virus tetanus others enables customised pro tection horse limited needle injections product portfolio indicat ions brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs dysfunction ppid asso ciated pituitary pars intermedia dysfunction ppid also known equine cushings disease way combination vetera eastern western venezuelan vaccination healthy horses vaccines common encephalomyelitis tetanus west aid prevention diseases caused diseases horses nile virus equine included antigens us canada herpes virus equine influenza viruses acute chronic obstructive ventipulmin clenbuterol treatment respiratory disease horses respiratory diseases airway obstruction due bron chospasm andor accumulation mucus contributing factor improved mucociliary clearance desirable recurrent airway obstruction equisolon prednisolone treatment recurrent airway rao heaves obstruction rao heaves horses combination environmental measures product portfolio animal health boehringer ingelheim companion animals small animals main small animal products address major chronic prozinc aqueous protamine zinc pzi suspension diseases heart failure kidney disease epilepsy oste recombinant human insulin used reduce oarthritis hyperglycaemia cats diabetes mellitus first new class heart treatments termed semintra angiotensin ii antagonist inodilators vetmedin shown significantly approved reduction proteinuria associated improve clinical signs extend life expectancy dogs chronic kidney disease ckd cats semintra congestive heart failure originating dilated decreases mean arterial blood pressure proteinuria cardiomyopathy valvular insufficiency mitral andor available oral solution tricuspid regurgitation vetmedin works two complementary modes action opens blood pexion alternative treatment canine epilepsy vessels taking blood away heart thereby active substance imepitoin primarily inhibits lowering pressure heart reducing seizures via potentiation gabaareceptormediated work heart pump blood around dogs inhibitory effects neurons pexion approved body time vetmedin direct effect reduction generalised seizures due idiopathic epi heart muscle helping beat stronger pump lepsy potential safety benefits existing blood efficiently standard treatment metacam nonsteroidal antiinflammatory drug duramune bronchishield vaccines designed nsaid available oral suspension tablets aid prevention wide spectrum common injectable solution dogs oral suspen infectious diseases dogs diseases sion injectable solution cats dogs indica serious cases even fatal effective preven tions include alleviation inflammation pain tion including appropriate vaccination reduces impact acute chronic musculoskeletal disorders diseases dogs well reduction postoperative pain following surgery cats indications include alleviation inflammation pain acute chronic musculo skeletal disorders well alleviation mild moderate postoperative pain following surgical proce dures variety formulations offers veterinarians owners flexibility use formulations prefer manage various levels inflammation pain associated licensed indications product portfolio indicat ions brand names active ingredients congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originated dilatative cardio myophathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopa thy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter doberman pinschers following echo cardiographic diagnosis cardiac disease pain inflammatory metacam meloxicam dogs metacam used reduce diseases postoperative pain inflammation following orthopaedic eg fracture oper ation soft tissue surgery cats metacam used reduce postoperative pain inflammation ovariohysterectomy spay opera tion orthopaedic minor soft tissue surgery moreover used alleviation pain inflammation acute chronic musculoskeletal disorders dogs cats feline diabetes mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical signs human insulin cats diabetes mellitus feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cats canine idiopathic epilepsy pexion imepitoin reduction frequency generalised seizures due idiopathic epilepsy dogs careful evaluation alternative treatment options canine infectious diseases duramune inactivated attenuated vaccine vaccination healthy dogs aid bronchishield canine distemper canine prevention diseases caused adenovirus type coronavirus included antigens us canada parainfluenzavirus parvovirus australia borrelia burgdorferi leptospira canicolagrippotyphosa icterohaemor rhagiae pomona bordetella bronchi septica comparison balance sheets boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheets millions eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable incl deferred charges deferred taxes liquid funds current assets incl deffered charges deferred taxes total assets liabilities equity december shareholders capital reserves incl currency conversion difference net income total equity minority interests group equity negative difference acquisition companies provisions incl deferred taxes liabilities incl deferred charges total liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return shareholders equity equity ratio cash flow financial funds personnel costs personnel costs net sales average number employees research development costs r net sales investments tangible assets depreciation tangible assets imprint assets december intangible assets tangible assets financial assets boehringer ingelheim gmbh binger strae fixed assets ingelheim inventories germany accounts receivable incl deferred charges deferred taxes telephone fax liquid funds current assets incl deffered charges deferred taxes contact total assets corporate division communications email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom liabilities equity december shareholders capital issued reserves incl currency conversion difference boehringer ingelheim gmbh net income concept design layout total equity mpm corporate communication solutions mainz minority interests wwwmpmde group equity negative difference acquisition companies photos provisions incl deferred taxes dieth schrder fotografie p liabilities incl deferred charges printed total liabilities incl deferred taxes deferred charges neue sddeutsche verlagsdruckerei gmbh ulm total liabilities equity copyright boehringer ingelheim gmbh summary selected financial data rights reserved part annual report may net sales reproduced transmitted form means operating income electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used operating income net sales annual report based data available time income taxes financial statement drawn income taxes net sales return shareholders equity equity ratio cash flow financial funds personnel costs personnel costs net sales average number employees research development costs r net sales investments tangible assets depreciation tangible assets